<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vancomycin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vancomycin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vancomycin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10037" href="/d/html/10037.html" rel="external">see "Vancomycin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11281" href="/d/html/11281.html" rel="external">see "Vancomycin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F52879177"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of embryo-fetal toxicity due to excipients:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A formulation of vancomycin injection contains the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA), which resulted in fetal malformations in animal reproduction studies at dose exposures approximately 8 and 32 times, respectively, higher than the exposures at the human equivalent dose. If use of vancomycin is needed during the first or second trimester of pregnancy, use other available formulations of vancomycin.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233330"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Firvanq;</li>
<li>Vancocin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868569"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP Vancomycin;</li>
<li>JAMP-Vancomycin;</li>
<li>PMS-Vancomycin;</li>
<li>PMSC-Vancomycin;</li>
<li>Vancocin;</li>
<li>Vancomycin HCl</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050536"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block don drugH1Div" id="F53462617"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing presented in mg/kg/dose and mg/kg/<b>day</b>; routes of administration may vary (IV, oral, intrathecal); use caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Determination of dosing interval requires consideration of multiple factors including concomitant medications (eg, ibuprofen, indomethacin), history of birth depression, birth hypoxia/asphyxia, and presence of cyanotic congenital heart disease. Dosage should be individualized based upon serum concentration monitoring. Utilize local antibiogram and protocols for further guidance. Optimal dose and frequency not established in extracorporeal membrane oxygenation (ECMO) patients; available data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8723454','lexi-content-ref-32296501','lexi-content-ref-9758319','lexi-content-ref-28650363','lexi-content-ref-30063652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8723454','lexi-content-ref-32296501','lexi-content-ref-9758319','lexi-content-ref-28650363','lexi-content-ref-30063652'])">Ref</a></span>). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO circuitry/filters as well as potential use of renal replacement therapies make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial dosage recommendations:</i> Note: </b>Use of a model-based approach for individualizing empiric dosing regimens may result in higher likelihood of target attainment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31108184','lexi-content-ref-29294072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31108184','lexi-content-ref-29294072'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Postmenstrual age-directed dosing: </i>Various dosing regimens have been studied; optimal dose not established. Consider risks and benefits of different regimens, infectious indication, and clinical status of patient; monitor closely.</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34843669','lexi-content-ref-31049551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34843669','lexi-content-ref-31049551'])">Ref</a></span>): <b>Note: </b>Dosing based on a pharmacokinetic model and randomized trial comparing a "standard" vancomycin regimen for 10 days and an "optimized" regimen for 5 days in a total of 242 patients with mostly culture-negative or coagulase-negative staphylococcus sepsis; patients with <i>Staphylococcus aureus</i> bacteremia were excluded from the randomized outcomes trial.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>"Standard regimen"</i>: <b>Note: </b>Standard regimen was associated with similar or better efficacy and less ototoxicity compared to the optimized regimen; however, a pharmacokinetic model showed this standard regimen was less likely than the optimized regimen to achieve the pharmacodynamic target (AUC<sub>24</sub> ≥400 mg•hour/L) desired for treatment of <i>S. aureus</i> infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34843669','lexi-content-ref-31049551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34843669','lexi-content-ref-31049551'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:12em;">
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Postmenstrual Age</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;29 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">29 to 35 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;35 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">
<i>"Optimized regimen"</i>: <b>Note: </b>Optimized regimen was associated with more ototoxicity and similar or worse efficacy; however, a pharmacokinetic model showed the optimized regimen is more likely than the standard regimen to achieve the pharmacodynamic target (AUC<sub>24</sub> ≥400 mg•hour/L) desired for treatment of <i>S. aureus</i> infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34843669','lexi-content-ref-31049551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34843669','lexi-content-ref-31049551'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:12em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Postmenstrual Age</p></th>
<th align="left">
<p style="text-indent:0em;">Loading Dose</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;29 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">29 to 35 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;35 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg/dose every 8 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Kidney function-based dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-11549096','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-11549096','lexi-content-ref-AAP.1'])">Ref</a></span>): <b>Note:</b> Serum creatinine fluctuates and may be influenced by maternal concentrations during the first week of life; use caution and frequently reassess renal function in neonates ≤7 days old receiving vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>). Dosing regimen was designed for a target trough concentration of 5 to 10 mg/L, though this may not be the optimal target based on newer data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11549096','lexi-content-ref-35037934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11549096','lexi-content-ref-35037934'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:10em;">Loading dose: All patients: IV: 20 mg/kg once, followed by maintenance dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Maintenance dose: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:12em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">Gestational</p>
<p style="text-indent:0em;">Age</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Serum</p>
<p style="text-indent:0em;">Creatinine</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" rowspan="5" valign="middle">
<p style="text-indent:0em;">≤28 weeks</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">&lt;0.5 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 to 0.7 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">20 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.8 to 1 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.1 to 1.4 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&gt;1.4 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 48 hours</p></td></tr>
<tr>
<td align="center" rowspan="5" valign="middle">
<p style="text-indent:0em;">&gt;28 weeks</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">&lt;0.7 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.7 to 0.9 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">20 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 to 1.2 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.3 to 1.6 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&gt;1.6 mg/dL</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">15 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis; treatment: Note: </b>For neonates &lt;2 kg, consider use of smaller doses and longer intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">PNA ≤7 days and ≥2 kg: IV: Initial: 20 to 30 mg/kg/<b>day</b> divided every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">PNA &gt;7 days and ≥2 kg: IV: Initial: 30 to 45 mg/kg/<b>day</b> divided every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventriculitis (including health care-associated ventriculitis and cerebrospinal fluid [CSF] shunt infections):</b> Limited data available: Intraventricular or intrathecal: <b>Use a preservative-free preparation: </b>3 to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-26039127','lexi-content-ref-29067501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-26039127','lexi-content-ref-29067501'])">Ref</a></span>); a dose of 5 mg is likely sufficient in neonates based on a study of 13 neonates which compared CSF vancomycin concentrations in patients receiving 5, 10, and 20 mg doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26039127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26039127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing: Altered Kidney Function: Neonatal:</b> IV: Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline.</p></div>
<div class="block dop drugH1Div" id="F233358"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> For IV dosing, initial dosage recommendations for patients with normal kidney function presented; doses should be adjusted based on serum concentration monitoring; doses require adjustment in renal impairment. Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline. Dosing presented in mg/kg/dose and mg/kg/<b>day</b>; routes of administration may vary (eg, IV, oral, intrathecal, intracatheter, intraperitoneal, rectal); use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Optimal dose and frequency not established in patients receiving extracorporeal membrane oxygenation (ECMO); available data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8723454','lexi-content-ref-9758319','lexi-content-ref-2225752','lexi-content-ref-30063652','lexi-content-ref-16120065','lexi-content-ref-30181721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8723454','lexi-content-ref-9758319','lexi-content-ref-2225752','lexi-content-ref-30063652','lexi-content-ref-16120065','lexi-content-ref-30181721'])">Ref</a></span>). Patient-specific considerations (eg, reason for ECMO) and variability with ECMO procedure itself make extrapolation of pharmacokinetic data and dosing to all patients receiving ECMO difficult; closely monitor serum concentrations and determine individual dosing needs in these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents: IV: Initial: 45 to 60 mg/kg/<b>day</b> divided every 6 to 8 hours; dose and frequency should be individualized based on serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note: </b>Based on adult data, an AUC<sub>24 </sub>target of 400 mg•hour/L is recommended in patients with serious methicillin-resistant <i>S. aureus</i> (MRSA) infections; specific dosing recommendations may be higher when targeting this range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). See "MRSA infection, serious; treatment".</p>
<p style="text-indent:-2em;margin-left:4em;">In general, monitoring of serum concentrations and assurance of adequate hydration status is recommended; utilize local antibiogram and protocols for further guidance.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af51f191-c90b-461a-ba89-7ebba0a0a742">Antibiotic lock therapy; catheter salvage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibiotic lock therapy; catheter salvage:</b> Limited data available: Optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For infections caused by susceptible organisms when the vascular catheter cannot be removed; use in addition to systemic antibiotics. Catheter salvage not effective in all cases; removal of catheter is recommended for infections with <i>S. aureus</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31725118','lexi-content-ref-19489710','lexi-content-ref-24923808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31725118','lexi-content-ref-19489710','lexi-content-ref-24923808'])">Ref</a></span>). Dosing regimens variable; consider age and size of patient and catheter size (including number of lumens) when determining dose due to potential for lock to be delivered intravenously.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Intracatheter: Usual concentrations of lock solution: 2 to 5 mg/mL of vancomycin with or without heparin additive; most common concentrations reported: vancomycin 2 mg/mL, 2.5 mg/mL, or 5 mg/mL; refer to institutional protocol if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25311403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25311403'])">Ref</a></span>). Concentrations described in literature range from 0.025 to 10 mg/mL with or without heparin or citrate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25548523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25548523'])">Ref</a></span>); a vancomycin concentration of 5 mg/mL has been shown to be more efficacious than 1 mg/mL when biofilm present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16556639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16556639'])">Ref</a></span>). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter, with a dwell time of ideally ≥8 to 12 hours and up to 72 hours, depending on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25548523','lexi-content-ref-25311403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25548523','lexi-content-ref-25311403'])">Ref</a></span>). <b>Note:</b> If heparin is utilized in the lock solution, the dose used should not approach therapeutic unit/kg dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f413d6d1-78b8-4352-bc3a-a2ee24c27fd9">C. difficile infection; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>C. difficile</i> infection; treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Infants, Children, and Adolescents: Oral: 40 mg/kg/<b>day</b> divided every 6 to 8 hours for 7 to 10 days; maximum daily dose: 2,000 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Guideline recommendations:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-severe infection, initial or first recurrence: </i>Children and Adolescents: Oral: 10 mg/kg/dose 4 times daily for 10 days; maximum dose: 125 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe/fulminant infection, initial: </i>Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 10 mg/kg/dose 4 times daily for 10 days; maximum dose: 500 mg/dose; may consider adding IV metronidazole in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>). If patient is unable to tolerate oral therapy, may use nasogastric administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27062204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27062204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Rectal: <b>Note: </b>Consider use when ileus is present. Limited data available: Rectal enema: 500 mg in 100 mL NS; dose volume is determined by age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>); the optimal doses have not been established in pediatric patients; suggested volumes for children: 1 to 3 years: 50 mL; 4 to 9 years: 75 mL; &gt;10 years: 100 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27062204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27062204'])">Ref</a></span>); administer 4 times daily with or without IV metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Second or subsequent recurrence:</i> Children and Adolescents: Pulsed-tapered regimen: Oral: 10 mg/kg/dose 4 times daily for 10 to 14 days; then 10 mg/kg/dose twice daily for 7 days, then 10 mg/kg/dose once daily for 7 days, then 10 mg/kg/dose every 2 or 3 days for 2 to 8 weeks; maximum dose: 125 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment: Note:</b> Dosage adjustment to target trough serum concentrations of 10 to 15 mg/L is recommended in pediatric endocarditis by the AHA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>). Dosage adjustment to target AUC<sub>24</sub> of 400 mg•hour/L has been recommended in the treatment of proven or suspected MRSA infections based on adult data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy/culture negative:</i> Children and Adolescents: IV: Initial: 60 mg/kg/<b>day</b> divided every 6 hours; initial maximum daily dose: 2,000 mg/<b>day</b>; use in combination with other antibiotics for at least 4 to 6 weeks; longer duration may be required if prosthetic material is present or in cases of recurrent endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Streptococcus (including enterococcus):</i> Children and Adolescents: IV: Initial: 40 mg/kg/<b>day</b> divided every 8 to 12 hours; initial maximum daily dose: 2,000 mg/<b>day</b>; treat for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Non-methicillin resistant: Children and Adolescents: IV: Initial: 40 mg/kg/<b>day</b> divided every 8 to 12 hours; initial maximum daily dose: 2,000 mg/<b>day</b>; treat for at least 4 to 6 weeks; a longer duration and additional antibiotics may be required depending on organism and presence of prosthetic material (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Methicillin-resistant: Children and Adolescents: IV: Initial: 40 mg/kg/<b>day</b> divided every 8 to 12 hours for at least 6 weeks; usual initial maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>); however, higher initial doses have been recommended for patients with serious MRSA infection with normal renal function, though dosing based on studies and models that were not specific to endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). See "MRSA infection, serious; treatment".</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4160ea9b-7a26-4a70-9278-a022f7877c28">Enterocolitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Enterocolitis (<i>S. aureus</i>):</b> Infants, Children, and Adolescents: Oral: 40 mg/kg/<b>day</b> divided every 6 to 8 hours for 7 to 10 days; maximum daily dose: 2,000 mg/<b>day.</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b012f8d-e5d6-4f21-ba34-047ac3e3be37">Meningitis, including health care-associated meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, including health care-associated meningitis:</b> Infants, Children, and Adolescents: IV: Initial: 15 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). Higher initial doses have been recommended for patients with serious MRSA infection with normal renal function, though dosing based on studies and models that were not specific to meningitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). See "MRSA infection, serious; treatment".</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc952319-847a-4e59-b4c7-f58d4e3a6c5d">MRSA infection, serious; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>MRSA infection, serious; treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Doses should be adjusted based on patient-specific serum concentrations to a target AUC<sub>24</sub> of 400 mg•hour/L, but potentially up to 600 mg•hour/L, based on adult data. In pediatric patients, an AUC<sub>24</sub> of ≥400 mg•hour/L has been associated with trough concentrations of 7 to 10 mg/L, though trough concentrations do not clearly predict AUC on an individual level and trough-only monitoring is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-23652479','lexi-content-ref-23340565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-23652479','lexi-content-ref-23340565'])">Ref</a></span>). Some studies have indicated that doses on the lower end of the range (ie, 60 mg/kg/<b>day</b> divided every 6 hours) will achieve target AUC<sub>24</sub> in most children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-23652479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-23652479'])">Ref</a></span>). To minimize risk of acute kidney injury, maintain AUC<sub>24</sub> &lt;800 mg•hour/L and trough &lt;15 mg/L. For obese patients, start with a one-time loading dose of 20 mg/kg (based on total body weight), then start maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months and Children &lt;12 years: IV: Initial: 60 to 80 mg/kg/<b>day</b> in divided doses every 6 hours; initial maximum daily dose: 3,600 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: Initial: 60 to 70 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; initial maximum daily dose: 3,600 mg<b>/day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Touch contamination of PD line (if known MRSA colonization): Intraperitoneal: 25 mg per liter.</p>
<p style="text-indent:-2em;margin-left:6em;">High-risk gastrointestinal procedures: <b>Note:</b> Use should be reserved for patients at high risk for MRSA: IV: 10 mg/kg administered 60 to 90 minutes before procedure; maximum dose: 1,000 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent: Intraperitoneal: Initial dose: 30 mg/kg in the long dwell; subsequent doses: 15 mg/kg/dose every 3 to 5 days during the long dwell; <b>Note:</b> Increased clearance may occur in patients with residual renal function; subsequent doses should be based on serum concentration obtained 2 to 4 days after the previous dose; redosing should occur when serum concentration &lt;15 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous: Intraperitoneal: Loading dose: 1,000 mg per liter of dialysate; maintenance dose: 25 mg per liter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Infants &gt;3 months, Children, and Adolescents: IV: Initial: 40 to 60 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>). <b>Note:</b> Higher doses may be necessary when treating MRSA infections; doses should be adjusted based on patient-specific serum concentrations to a target AUC<sub>24</sub> of 400 mg•hour/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). See "MRSA infection, serious; treatment".</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c22f541-3ab2-4888-be06-58bd9057595b">Skin and skin structure infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, complicated:</b>
<b>Note: </b>Duration of treatment should be individualized and is dependent on severity of infection, adequacy of source control, and clinical improvement. For necrotizing fasciitis, continue treatment until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Necrotizing infections, mixed (non-MRSA): Infants, Children, and Adolescents: IV: Initial: 10 to 13 mg/kg/dose every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Serious MRSA infection, including necrotizing infection and pyomyositis: <b>Note: </b>Dosage adjustment to target AUC<sub>24</sub> of 400 mg•hour/L recommended for serious MRSA infections based on adult data. A loading dose of 20 mg/kg (based on total body weight) is recommended in obese patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months and Children &lt;12 years: IV: Initial: 60 mg/kg/<b>day</b> in divided doses every 6 hours; maximum daily dose: 3,600 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-24947530'])">Ref</a></span>). Based on pharmacokinetic modeling studies, doses up to 80 mg/kg/<b>day</b> may be necessary to achieve target AUC<sub>24</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IV: Initial: 60 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum daily dose: 3,600 mg<b>/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-24947530'])">Ref</a></span>). Based on pharmacokinetic modeling studies, doses up to 70 mg/kg/<b>day</b> may be necessary to achieve target AUC<sub>24</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (perioperative) prophylaxis:</b> Infants, Children, and Adolescents: IV: 15 mg/kg/dose within 120 minutes prior to surgical incision. May be administered in combination with other antibiotics depending upon the surgical procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b330bb7d-417f-4302-93bf-7bacb1ea34aa">Ventriculitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventriculitis (including health care-associated ventriculitis and cerebrospinal fluid [CSF] shunt infections)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available: Intraventricular or intrathecal: <b>Use a preservative-free preparation</b>: 5 to 20 mg/<b>day</b>; usual dose: 10 or 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>); due to the smaller CSF volume in infants, some guidelines recommend decreasing the infant dose; adult dosage recommendations are based on ventricle size (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous infusion dosing:</b> Limited data available; optimal dosing unknown:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Loading dose: 10 to 15 mg/kg/dose administered over 1 to 2 hours, followed by maintenance infusion of 40 to 60 mg/kg/<b>day</b>; adjust dose to achieve target serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31591117','lexi-content-ref-29394210','lexi-content-ref-Girand.2019','lexi-content-ref-27631462','lexi-content-ref-29718415','lexi-content-ref-23172265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31591117','lexi-content-ref-29394210','lexi-content-ref-Girand.2019','lexi-content-ref-27631462','lexi-content-ref-29718415','lexi-content-ref-23172265'])">Ref</a></span>). <b>Note:</b> Required dose to achieve target concentration varies significantly between patients and depending on age, renal function, and target concentration; total daily doses of 30 to 110 mg/kg/<b>day</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31591117','lexi-content-ref-29718415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31591117','lexi-content-ref-29718415'])">Ref</a></span>). Pediatric patients with cancer or who are critically ill may require higher doses to achieve target concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29394210','lexi-content-ref-27631462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29394210','lexi-content-ref-27631462'])">Ref</a></span>). <b>Note:</b> When transitioning from intermittent to continuous infusion, an initial loading dose may not be required; the total daily dose will likely need reduced depending on patient-specific factors, concentrations achieved during intermittent dosing, and clinical considerations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29718415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29718415'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193236"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Note:</b> Vancomycin levels should be monitored in patients with any renal impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): <b>Note:</b> Renally-adjusted dose recommendations are based on intravenous doses of 10 mg/kg/dose every 6 hours or 15 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 18 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose; redose based on serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: 10 mg/kg/dose; redose based on serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): 10 mg/kg/dose; redose based on serum concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 12 to 24 hours; monitor serum concentrations.</p></div>
<div class="block dohp drugH1Div" id="F51193237"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely needed due to low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no dosage adjustments provided in the manufacturer's labeling; however, degrees of hepatic dysfunction do not affect the pharmacokinetics of vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8878246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8878246'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F233334"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10037" href="/d/html/10037.html" rel="external">see "Vancomycin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Risk of toxicity (eg, acute kidney injury) increases as a function of trough concentration, especially when trough is maintained above 15 to 20 mg/L; recent data suggest risk increases along the vancomycin AUC continuum, especially when daily AUC exceeds 650 to 1,300 mg•h/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Initial IV dosing in patients without obesity should be based on actual body weight; subsequent dosing should generally be adjusted based on therapeutic monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> The oral route is ineffective for treating systemic infections; the IV route is ineffective for treating <i>C. difficile</i> infection. Trough monitoring has traditionally been used for therapeutic monitoring; however, for serious methicillin-resistant S. aureus (MRSA) infections (eg, bacteremia, infective endocarditis, meningitis, osteomyelitis, pneumonia, sepsis), AUC monitoring is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). For patients with uncomplicated skin and soft tissue infections who are not obese and have normal renal function, therapeutic monitoring is generally not needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b> 125 to 500 mg 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent infusion</i>: 15 to 20 mg/kg/dose (rounded to the nearest 250 mg) every 8 to 12 hours initially; for serious MRSA infections (eg, bacteremia, infective endocarditis, meningitis, osteomyelitis, pneumonia, sepsis), adjust based on therapeutic monitoring to achieve a target AUC/minimum inhibitory concentration (MIC) determined by broth microdilution (MIC<sub>BMD</sub>) ratio of 400 to 600 (assuming a vancomycin MIC<sub>BMD</sub> of 1 mg/L). Trough-only monitoring (target trough: 15 to 20 mg/L) is no longer recommended in patients with serious MRSA infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>), but may be needed in nonserious MRSA or non-MRSA infections. Early and frequent monitoring for dosage adjustments is recommended, especially when empiric doses exceed 4 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: Seriously ill patients with documented/suspected MRSA infection: A loading dose of 20 to 35 mg/kg (based on actual body weight; maximum: 3 g/dose) may be considered to rapidly achieve target concentrations. After administration of the loading dose, the initiation of the maintenance dose should occur at the next dosing interval (eg, for a prescribed interval of every 8 hours, initiate the maintenance dose 8 hours after the start of the loading dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion</i>: <b>Note:</b> May be considered for critically ill patients who are unable to achieve AUC target with intermittent infusion dosing. Loading dose: 15 to 20 mg/kg, followed by a maintenance continuous infusion dose of 30 to 40 mg/kg/day (up to 60 mg/kg/day) to achieve a target steady state concentration of 20 to 25 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy or pathogen-specific therapy for methicillin-resistant S. aureus:</i>
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-21217178'])">Ref</a></span>). Treat uncomplicated <i>S. aureus</i> infection for ≥14 days from first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy or pathogen-specific therapy for methicillin-resistant coagulase-negative staphylococci:</i>
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring. Treat uncomplicated bacteremia for 5 to 7 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-Tufariello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-Tufariello.1'])">Ref</a></span>). For catheter-related bloodstream infections, consider antibiotic lock therapy for catheter salvage, in addition to systemic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antibiotic lock technique</i>
<i>(catheter-salvage strategy) (off-label use)</i>: <b>Note:</b> For infections caused by susceptible organisms when the catheter cannot be removed; use in addition to systemic antibiotics. Catheter salvage is <b>not</b> recommended for <i>S. aureus </i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Girand.2019','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Girand.2019','lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intracatheter:</b> Prepare lock solution to final concentration of vancomycin 2.5 to 5 mg/mL; may be combined with heparin. Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of up to 72 hours, depending on frequency of catheter use. Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-17403700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-17403700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0161ba30-daf5-44e8-a055-5635faa343ea">Cerebrospinal fluid shunt infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebrospinal fluid shunt infection (off-label use): </b>
<b>As a component of</b>
<b>empiric therapy or pathogen-specific therapy (eg, methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b> or coagulase-negative staphylococci</b>
<b>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraventricular</b> (adjunct to systemic therapy; use a preservative-free preparation): 5 to 20 mg/day; some experts recommend adjusting dosage and administration interval based on cerebrospinal fluid (CSF) vancomycin concentrations (goal: 10 to 20 times MIC of causative organism), ventricular size, and daily output from ventricular drain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>); data for monitoring are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29518176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29518176'])">Ref</a></span>). When intraventricular vancomycin is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). <b>Note:</b> Intraventricular administration is generally reserved for use in patients who fail parenteral therapy despite removal of CSF shunt or when CSF shunt cannot be removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5aea94f0-cdab-48d8-a2fa-64de68a2cca2">
<i>Clostridioides difficile</i> infection, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients with a recent history of <i>C. difficile</i> infection (CDI) who subsequently require systemic antibiotics. Some experts reserve for patients who are older (≥65 years of age) or are significantly immunocompromised who have been hospitalized with severe CDI in the past 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176'])">Ref</a></span>); other experts consider use for any patients with CDI in the prior 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>125 mg once daily; continue for 5 to 7 days after completion of systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-Kelly.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c05ef37d-c875-44c5-bf42-41a4ee5c44d5">
<i>Clostridioides difficile</i> infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Criteria for disease severity is based on expert opinion and should not replace clinical judgment. There is no role for vancomycin doses other than 125 mg and 500 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial, nonfulminant infection (alternative agent):</i>
<b>Oral: </b>125 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>). Usual duration is 10 days; if delayed response to treatment, a longer duration (eg, up to 14 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>). If antibiotic(s) for a primary infection are essential, some experts extend CDI treatment one week beyond other antibiotic(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Recurrent, nonfulminant infection (alternative agent): </i>
<b>Note: </b>Regimen selection depends on prior treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 125 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164674'])">Ref</a></span>). Some experts reserve for patients who did not receive vancomycin for the initial episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164674'])">Ref</a></span>). Usual duration is 10 days; if delayed response to treatment, a longer duration (eg, up to 14 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>). If antibiotic(s) for a primary infection are essential, some experts extend CDI treatment one week beyond other antibiotic(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulsed-tapered regimen: <b>Oral: </b>125 mg 4 times daily for 10 to 14 days, then 125 mg twice daily for 7 days, then 125 mg once daily for 7 days, then 125 mg every 2 or 3 days for 2 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Combination regimen with rifaximin: <b>Note: </b>Rifaximin resistance may be a concern; some experts avoid in patients who have previously received rifamycins, and others do not routinely recommend this regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>125 mg 4 times daily for 10 days followed by rifaximin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fulminant infection (ie, ileus, megacolon, and/or hypotension/shock):</i>
<b>Oral or via nasogastric tube:</b> 500 mg 4 times daily with IV metronidazole; if ileus is present, may consider vancomycin retention enema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>). Usual duration is 10 days; if delayed response to treatment, a longer duration (eg, up to 14 days) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>). If antibiotic(s) for a primary infection are essential, some experts extend CDI treatment one week beyond other antibiotic(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fulminant infection with ileus:</i>
<b>Rectal retention enema (off-label route): </b>500 mg in 100 mL NS; retained for as long as possible and replaced every 6 hours. Use in combination with oral vancomycin (if the ileus is partial) or in place of oral vancomycin (if the ileus is complete) <b>plus</b> IV metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176'])">Ref</a></span>). <b>Note: </b>Optimal regimen not established. Use of rectal vancomycin should be reserved for patients who have not responded to standard therapy and performed by individuals with expertise in administration, as there is risk of colonic perforation. Usual duration is 10 days; if delayed response to treatment, a longer duration (eg, up to 14 days) may be considered. If antibiotic(s) for a primary infection are essential, some experts extend CDI treatment one week beyond other antibiotic(s) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kelly.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0b5bc48-b987-4330-955e-e3bf18ae8c5e">Cystic fibrosis, acute pulmonary exacerbation, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation, moderate to severe (off-label use):</b> Empiric or pathogen-directed therapy for methicillin-resistant <i>S. aureus</i>: <b>IV:</b> 15 to 20 mg/kg/dose every 8 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29290740','lexi-content-ref-Simon.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29290740','lexi-content-ref-Simon.2019'])">Ref</a></span>). Duration is usually 10 to 14 days depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-34469706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (off-label use):</b> Empiric or pathogen-directed therapy for methicillin-resistant <i>S. aureus</i>: <b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration (which may include appropriate oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Enterococcus (native or prosthetic valve) (penicillin-resistant strains or patients unable to tolerate beta-lactams):</i>
<b>IV:</b> 15 mg/kg/dose every 12 hours initially; adjust to obtain a trough concentration of 10 to 20 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>); some experts favor a trough of 15 to 20 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22086858','lexi-content-ref-26320109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22086858','lexi-content-ref-26320109'])">Ref</a></span>). Administer in combination with gentamicin for 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>S. aureus, methicillin-resistant or methicillin-susceptible (severe-beta lactam hypersensitivity) (alternative agent):</i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Native valve: 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-32191793'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration of therapy is 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Prosthetic valve: 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-32191793'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration of therapy is at least 6 weeks (combine with rifampin for the entire duration of therapy and gentamicin for the first 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-21217178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Viridans group streptococci and S. bovis (native or prosthetic valve) (penicillin or ceftriaxone intolerance):</i>
<b>IV:</b> 15 mg/kg/dose every 12 hours initially; adjust based on therapeutic monitoring. Duration of therapy is 4 weeks (native valve) or 6 weeks (prosthetic valve) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a15a5818-14e1-4603-972a-fa7e40d98308">Endophthalmitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endophthalmitis, treatment (off-label use):</b>
<b>Intravitreal:</b> Usual dose: 1 mg per 0.1 mL NS or sterile water injected into vitreum, usually in combination with ceftazidime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.1','lexi-content-ref-7487614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.1','lexi-content-ref-7487614'])">Ref</a></span>). A repeat dose(s) may be considered at 24 to 48 hours based on culture result, severity of the infection, and response to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c82164-6e39-49fb-b6e3-a16936479eb4">Intra-abdominal infection, health care–associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, health care–associated (off-label use):</b>
<i>Empiric or pathogen-directed therapy for Enterococcus spp. in high-risk patients (eg, postoperative infection or health care<b>–</b>associated infection in patients with prior use of antibiotics that select for Enterococcus, immunocompromising condition, valvular heart disease, or prosthetic intravascular material):</i>
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-20034345'])">Ref</a></span>). Use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>). Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a47b3dd-219d-422b-bc94-4af729bacffc">Intracranial abscess or spinal epidural abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess, intracranial epidural abscess) or spinal epidural abscess (off-label use): As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b>: IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring. A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-21217178'])">Ref</a></span>). Duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess and 6 to 8 weeks for intracranial epidural abscess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29909695','lexi-content-ref-Sexton.2019b','lexi-content-ref-Sexton.2019a','lexi-content-ref-Southwick.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29909695','lexi-content-ref-Sexton.2019b','lexi-content-ref-Sexton.2019a','lexi-content-ref-Southwick.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (off-label use):</b>
<b>As a component of</b>
<b>empiric therapy or pathogen-specific therapy (eg, methicillin-resistant </b>
<i>
<b>S. aureus </b></i>
<b>or penicillin- and cephalosporin-resistant <i>S. pneumoniae</i>): IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-21217178'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis</b>
<b>:</b>
<b> As a component of empiric therapy or pathogen-specific therapy (eg, methicillin-resistant <i>S. aureus</i>): IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-21217178'])">Ref</a></span>); adjust based on therapeutic monitoring. A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration is generally ≥6 weeks; shorter courses are appropriate if the affected bone is completely resected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (peritoneal dialysis patients) (off-label use):</b>
<b>Note:</b> Intraperitoneal administration is preferred to IV administration. Adjust to obtain a trough concentration between 15 and 20 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>). Consider a 25% dose increase in patients with significant residual renal function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20628102','lexi-content-ref-27282851','lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent (preferred): <b>Intraperitoneal:</b> 15 to 30 mg/kg added to one exchange of dialysate every 5 to 7 days (allow to dwell for ≥6 hours); supplemental doses and more frequent monitoring of serum levels may be needed for patients receiving automated peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous (with every exchange): <b>Intraperitoneal:</b> Loading dose: 30 mg/kg added to first exchange of dialysate; maintenance dose: 1.5 mg/kg/bag for each subsequent exchange of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6627823','lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6627823','lexi-content-ref-27282851'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, as a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus: </b></i>
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-21217178','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-21217178','lexi-content-ref-31573350'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19106348','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19106348','lexi-content-ref-21217178'])">Ref</a></span>). <b>Note:</b> Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days. When used for empiric therapy, give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-27418577','lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-27418577','lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use):</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-specific therapy for methicillin-resistant or susceptible S. aureus (alternative agent in beta-lactam intolerance):</i> 15 to 20 mg/kg/dose every 8 to 12 hours initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-21217178','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-21217178','lexi-content-ref-23223583'])">Ref</a></span>); adjust based on therapeutic monitoring. A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-specific therapy for Enterococcus</i>
<i>spp (penicillin susceptible [alternative agent] or penicillin resistant)</i>: 15 mg/kg/dose every 12 hours initially; adjust based on therapeutic monitoring. Duration: 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> In select cases (eg, debridement and retention of prosthesis or one-stage arthroplasty), give oral suppressive antibiotic therapy with an appropriate regimen following completion of initial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="950785bc-fad3-4a9d-9979-9a1ae6536911">Sepsis/septic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis/septic shock:</b>
<b>As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b>: IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). A loading dose is recommended; administer within 1 hour of suspected or confirmed sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-34599691'])">Ref</a></span>). Duration is dependent on underlying source and patient response; short courses are preferred, when appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b95c4e6-731a-4c54-a07f-d029033f2fd8">Septic arthritis, without prosthetic material</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis, without prosthetic material:</b>
<b>As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b> or coagulase-negative staphylococci: IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust dose on therapeutic monitoring. A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including appropriate oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1','lexi-content-ref-21217178'])">Ref</a></span>); some experts recommend 4 weeks of parenteral therapy for patients with concomitant bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (hospitalized patient): As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b>:</b>
<b>IV:</b> 15 mg/kg/dose every 12 hours initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>). For patients with uncomplicated skin and soft tissue infections who are not obese and have normal renal function, therapeutic monitoring is generally not needed; for complicated or severe infections, adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-24947530'])">Ref</a></span>). <b>Note:</b> For empiric therapy of necrotizing infection, must be used in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f8fdde6-bbf9-4ed3-99cc-d4e05b77b439">
<i>Streptococcus</i>, maternal prophylaxis for prevention of neonatal disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i> (group B), maternal prophylaxis for prevention of neonatal disease (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 20 mg/kg at the onset of labor or prelabor rupture of membranes, then every 8 hours until delivery; maximum single dose: 2 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31977795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31977795'])">Ref</a></span>). Some experts prefer vancomycin 2 g initially and then 1 g every 12 hours thereafter until delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baker.1'])">Ref</a></span>). <b>Note:</b> Vancomycin is reserved for patients with penicillin allergy at high risk for anaphylaxis that have documented clindamycin-resistant group B <i>Streptococcus</i> or no available susceptibility data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31977795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31977795'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (in combination with other appropriate agents when coverage for methicillin-resistant <i>S. aureus </i>is indicated or for gram-positive coverage in patients unable to tolerate beta-lactams) (off-label use): IV:</b> 15 mg/kg (usual maximum: 2 g/dose initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Anderson.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Anderson.2020'])">Ref</a></span>)) started within 60 to 120 minutes prior to initial surgical incision. Vancomycin doses may be repeated intraoperatively in 2 half-lives (approximately 8 to 12 hours in patients with normal renal function) if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24799638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24799638'])">Ref</a></span>). <b>Postoperative</b> prophylaxis is not recommended in clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b86aa8e-9c80-4250-bfe7-202ab443aa9d">Surgical site infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical site infection:</b>
<b>As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S.</b></i>
<i>
<b>aureus</b></i>
<b>: IV:</b> 15 mg/kg/dose every 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0147eb6-43ef-491e-b940-9b06d9b5e5ab">Toxic shock syndrome, staphylococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic shock syndrome, staphylococcal: As a component of empiric therapy or pathogen-specific therapy for methicillin-resistant </b>
<i>
<b>S. aureus</b></i>
<b>:</b>
<b>IV:</b> 15 to 20 mg/kg/dose every 8 to 12 hours initially; adjust based on therapeutic monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-Chu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-Chu.1'])">Ref</a></span>). A loading dose may be considered in seriously ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). Duration varies based on underlying etiology; 10 to 14 days of treatment is recommended in the absence of bacteremia or other distinct focus of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990835"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initial IV dosing in nonobese patients should be based on actual body weight; subsequent dosing should generally be adjusted based on therapeutic monitoring. Trough monitoring has traditionally been used for therapeutic monitoring; however, for serious methicillin-resistant <i>S. aureus</i> (MRSA) infections (eg, bacteremia, infective endocarditis, meningitis, osteomyelitis, pneumonia, sepsis), AUC monitoring is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). A ratio of AUC over 24 hours to minimum inhibitory concentration (AUC/MIC) of ≥400 is the primary pharmacokinetic/pharmacodynamic predictor of vancomycin efficacy in serious MRSA infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-23335735','lexi-content-ref-21460309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-23335735','lexi-content-ref-21460309'])">Ref</a></span>). Serum concentration monitoring should be conducted within the first 48 hours of therapy for patients with suspected or documented serious infections due to MRSA, with subsequent dosing adjusted to maintain AUC/MIC between 400 to 600 in order to maximize efficacy and minimize risk of vancomycin nephrotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-15509186','lexi-content-ref-23147106','lexi-content-ref-29084753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-15509186','lexi-content-ref-23147106','lexi-content-ref-29084753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent infusion:</i>
<b> Note:</b> The following table provides general recommendations (expert opinion derived from ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Golightly 2013). Refer to institution-specific policies and procedures for more detailed guidance.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Vancomycin Initial Dose Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">Suggested loading dose (when applicable)<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Suggested initial maintenance dose</p></th>
<th align="center">
<p style="text-indent:0em;">Suggested dosing interval</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>Loading doses recommended in critically ill patients with suspected/documented serious MRSA infections. A loading dose of up to 35 mg/kg may be considered in critically ill patients with sepsis. Obese patients usually require 20 to 25 mg/kg loading doses. Maximum recommended loading dose is 3 g (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:0em;">
<sup>b</sup>Monitor vancomycin serum concentrations more frequently, especially early on in therapy, to achieve target concentrations as these patients may have unstable or less predictable drug clearance. Care should be taken not to administer maintenance doses when serum concentrations remain &gt;20 mg/L (Golightly 2013; expert opinion).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;90 to &lt;130</p></td>
<td align="center">
<p style="text-indent:0em;">25 to 30 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 to 20 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">8 to 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to 90</p></td>
<td align="center">
<p style="text-indent:0em;">20 to 25 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 to 20 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;50</p></td>
<td align="center">
<p style="text-indent:0em;">20 to 25 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 15 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">20 to 25 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 15 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 72 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: Administer an appropriate loading dose (eg, 15 to 20 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-25475123','lexi-content-ref-19223642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-25475123','lexi-content-ref-19223642'])">Ref</a></span>); higher loading doses may be considered in critically ill patients with sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27216073','lexi-content-ref-22333933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27216073','lexi-content-ref-22333933'])">Ref</a></span>); also refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: Various protocols have been developed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25475123','lexi-content-ref-27216073','lexi-content-ref-22333933','lexi-content-ref-19223642','lexi-content-ref-26116239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25475123','lexi-content-ref-27216073','lexi-content-ref-22333933','lexi-content-ref-19223642','lexi-content-ref-26116239'])">Ref</a></span>); recommendations may vary based on the population studied. The following is an example protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27216073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27216073'])">Ref</a></span>), and doses should be adjusted to achieve a target steady state concentration of 20 to 25 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>); also refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &gt;80 to 119 mL/minute: 30 mg/kg administered over 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &gt;50 to 80 mL/minute: 25 mg/kg administered over 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl 25 to 50 mL/minute:14 mg/kg administered over 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &lt;25 mL/minute: 7 mg/kg administered over 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent infusion:</i> Loading dose (when applicable): 25 to 35 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) followed by 15 to 20 mg/kg every 8 hours depending on degree of augmented kidney function; some patients may require more frequent dosing (eg, 15 mg/kg every 6 hours) to attain target concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31722513','lexi-content-ref-25627406','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31722513','lexi-content-ref-25627406','lexi-content-ref-Expert.DOR'])">Ref</a></span>); utilize frequent serum concentration monitoring.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: Administer an appropriate loading dose (eg, 15 to 20 mg/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793','lexi-content-ref-25475123','lexi-content-ref-19223642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793','lexi-content-ref-25475123','lexi-content-ref-19223642'])">Ref</a></span>); higher loading doses (eg, 25 mg/kg) have been used in some protocols and may vary based on population studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27216073','lexi-content-ref-31600554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27216073','lexi-content-ref-31600554'])">Ref</a></span>); also refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: 40 to 60 mg/kg/day depending on degree of augmented kidney function with frequent serum concentration monitoring; adjust to achieve a target steady state concentration of 20 to 25 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25475123','lexi-content-ref-27216073','lexi-content-ref-19223642','lexi-content-ref-24165255','lexi-content-ref-31600554','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25475123','lexi-content-ref-27216073','lexi-content-ref-19223642','lexi-content-ref-24165255','lexi-content-ref-31600554','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (25% to 40% depending on dialyzer permeability) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12198218','lexi-content-ref-29380499','lexi-content-ref-9085316']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12198218','lexi-content-ref-29380499','lexi-content-ref-9085316'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Vancomycin Dosing Depending on Dose Timing and Dialyzer Permeability<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose timing and dialyzer permeability</p></th>
<th align="center">
<p style="text-indent:0em;">Vancomycin dose<sup>b</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>ASHP/IDSA/PIDS/SIDP [Rybak 2020]</p>
<p style="text-indent:0em;">
<sup>b</sup>Initial recommended loading/maintenance doses. The optimal pharmacokinetic/pharmacodynamic target in this population is unknown, but targeting predialysis concentrations of 15 to 20 mg/L are likely to achieve AUCs of 400 to 600 mg•hour/L (ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Crew 2015). Predialysis serum concentrations should be obtained no less than weekly and should determine subsequent dosing (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:0em;">
<sup>c</sup>Thrice-weekly dose administration. Typically, patients may require ~25% larger doses for the 3-day interdialytic period (eg, Friday to Monday) to maintain sufficient vancomycin exposure on the third day.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<b>Dose given after dialysis ends</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Low permeability (low flux)</p></td>
<td align="center">
<p style="text-indent:0em;">Loading dose: 25 mg/kg</p>
<p style="text-indent:0em;">Maintenance dose: 7.5 mg/kg<sup>c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">High permeability (high flux)</p></td>
<td align="center">
<p style="text-indent:0em;">Loading dose: 25 mg/kg</p>
<p style="text-indent:0em;">Maintenance dose: 10 mg/kg<sup>c</sup></p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">
<b>Dose given during last hours of dialysis (intradialytic)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Low permeability (low flux)</p></td>
<td align="center">
<p style="text-indent:0em;">Loading dose: 30 mg/kg</p>
<p style="text-indent:0em;">Maintenance dose: 7.5 to 10 mg/kg<sup>c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">High permeability (high flux)</p></td>
<td align="center">
<p style="text-indent:0em;">Loading dose: 35 mg/kg</p>
<p style="text-indent:0em;">Maintenance dose: 10 to 15 mg/kg<sup>c</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 20 to 25 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). A vancomycin serum concentration should be obtained ~48 to 72 hours after the loading dose, and subsequent doses (usually 10 to 15 mg/kg) should be administered based on attainment of goal serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Doses may vary based on infection site and severity, as well as the presence or absence of residual renal function. Some experts use maintenance doses of up to 20 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drew.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drew.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 20 to 25 mg/kg followed by 7.5 to 10 mg/kg every 12 hours with more frequent serum concentration monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). In patients with suspected or confirmed serious MRSA infections, dose adjustments should be made based on AUC monitoring occurring in the first 24 to 48 hours of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (administer even if PIRRT is occurring): 20 to 25 mg/kg, followed by 15 mg/kg after each PIRRT session ends (or during the final 60 to 90 minutes of the session) with more frequent serum concentration monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>). In patients with suspected or confirmed serious MRSA infections, dose adjustments should be made based on AUC monitoring occurring in the first 24 to 48 hours of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32191793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32191793'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988057"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV: </b> There are no dosage adjustments provided in the manufacturer’s labeling. However, degrees of hepatic dysfunction do not affect the pharmacokinetics of vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8878246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8878246'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54416571"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anaphylaxis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Vancomycin may rarely cause life-threatening immune-mediated <b>anaphylaxis</b>, which may present as generalized and extensive <b>pruritus</b> and/or <b>erythema of skin</b>, respiratory distress, bronchospasm, hypoxia, and<b> hypotension</b>. Clinical presentation is similar to vancomycin infusion reaction (a nonimmune-mediated anaphylactoid <b>infusion-related reaction</b>; formerly called “red man syndrome”), making it difficult for clinicians to distinguish between the 2 reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7978531','lexi-content-ref-10875494','lexi-content-ref-11317179','lexi-content-ref-20234160','lexi-content-ref-27156746','lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7978531','lexi-content-ref-10875494','lexi-content-ref-11317179','lexi-content-ref-20234160','lexi-content-ref-27156746','lexi-content-ref-11724099'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic; IgE-mediated with specific antibodies formed against a drug allergen following initial exposure (immunologically mediated) or result in direct mast cell stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). IgE binding and cross-linking of the high affinity IgE receptor (FcεRI) on the surface of mast cells causes release of histamine and other mediators that can result in urticaria, flushing, airway obstruction, hypotension, and tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32001253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32001253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; IgE-mediated reactions generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.2020'])">Ref</a></span>). In a systematic review analyzing 7 case reports of vancomycin-induced anaphylaxis, the median time to onset of signs/symptoms was 2 minutes (range: 1 to 35 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27156746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27156746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Previous exposure to vancomycin (necessary for IgE-mediated anaphylaxis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14570656','lexi-content-ref-27156746','lexi-content-ref-26246124','lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14570656','lexi-content-ref-27156746','lexi-content-ref-26246124','lexi-content-ref-11724099'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although oral vancomycin is used for the treatment of <i>Clostridioides difficile</i> infection (CDI), <b>
<i>Clostridioides difficile</i>-associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis </b>have been reported with intravenous vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2910675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2910675'])">Ref</a></span>). Clinical symptoms range from mild diarrhea to life-threatening colitis, toxic megacolon, and sepsis. In patients with severe CDI, frequent symptoms include watery diarrhea, abdominal pain, fever, nausea, anorexia, and malaise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19209277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19209277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; antibiotics disrupt the indigenous gut microbiota which promotes <i>C. difficile</i> spore germination, growth, and toxin production, leading to epithelial damage and colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24503131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24503131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor); antibiotics most frequently associated with <i>C. difficile</i> include clindamycin, fluoroquinolones, and third-/fourth-generation cephalosporins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions or a serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29562266'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications, such as proton pump inhibitors and H2 blockers (suggested risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29562266','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced immune thrombocytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drug-induced<b> immune thrombocytopenia </b>(DITP) has been associated with use. Vancomycin-induced ITP has been associated with severe bleeding characterized by petechial hemorrhages, ecchymoses, and oozing from the buccal mucosa. Rarely, acutely-ill patients have experienced gross hematuria, lower GI hemorrhage, intrapulmonary hemorrhage, and excessive bleeding from venipuncture sites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26266247','lexi-content-ref-23845922','lexi-content-ref-26260647','lexi-content-ref-17665503','lexi-content-ref-OUHSC.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26266247','lexi-content-ref-23845922','lexi-content-ref-26260647','lexi-content-ref-17665503','lexi-content-ref-OUHSC.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic; platelet-reactive antibodies of the IgG class, the IgM class, or both, have been detected in patients with thrombocytopenia while receiving vancomycin. These antibodies reacted with platelets only in the presence of vancomycin, suggesting that the mechanism is similar to quinine-induced thrombocytopenia rather than a hapten-specific antibody (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17329697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17329697'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; DITP; typically occurs within 1 to 2 weeks after initiating therapy or longer in patients with intermittent exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17687133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17687133'])">Ref</a></span>). In case reports, the mean time to platelet nadir count was ~8 days following first exposure. However, there are rare case reports describing a rapid onset (within 24 hours) of acute severe thrombocytopenia, primarily in settings of reexposure to vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27848200','lexi-content-ref-17329697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27848200','lexi-content-ref-17329697'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Maculopapular rash </b>and severe cutaneous adverse reactions (SCARs), including <b>drug rash with eosinophilia and systemic symptoms </b>(DRESS), <b>toxic epidermal necrosis </b>(TEN),<b> Stevens-Johnson syndrome </b>(SJS), and<b> acute generalized exanthematous pustulosis </b>(AGEP), have occurred rarely with use and may be life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21738885','lexi-content-ref-21592453','lexi-content-ref-21273948','lexi-content-ref-15767246','lexi-content-ref-24599767','lexi-content-ref-9399623','lexi-content-ref-26561525','lexi-content-ref-30176295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21738885','lexi-content-ref-21592453','lexi-content-ref-21273948','lexi-content-ref-15767246','lexi-content-ref-24599767','lexi-content-ref-9399623','lexi-content-ref-26561525','lexi-content-ref-30176295'])">Ref</a></span>). In addition, vancomycin-induced <b>dermatologic disorder</b> (linear IgA bullous dermatosis [LABD]) has been reported rarely and clinical presentation may mimic TEN, making it difficult to distinguish (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23829415','lexi-content-ref-31110752','lexi-content-ref-15550142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23829415','lexi-content-ref-31110752','lexi-content-ref-15550142'])">Ref</a></span>). Other reactions include <b>erythema multiforme</b>, <b>exfoliative dermatitis</b>, and <b>hypersensitivity angiitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2139270','lexi-content-ref-31356340','lexi-content-ref-28943633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2139270','lexi-content-ref-31356340','lexi-content-ref-28943633'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. Delayed hypersensitivity reactions are mediated by T-cells or antibodies other than IgE (eg, IgG-mediated, such as some cytopenias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). SCARs are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>). The mechanism behind vancomycin-induced LABD is unknown; LABD is a rare immune-mediated blistering disorder resulting in linear deposition of IgA at the basement membrane zone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28168063','lexi-content-ref-9735094','lexi-content-ref-23829415','lexi-content-ref-31110752']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28168063','lexi-content-ref-9735094','lexi-content-ref-23829415','lexi-content-ref-31110752'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; type IV reactions are delayed hypersensitivity reactions that typically occur days to weeks after drug exposure but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2020'])">Ref</a></span>). DRESS usually does not develop until after 2 weeks of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30776417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30776417'])">Ref</a></span>). In a systematic case review, a median onset of 9 days and 21 days was observed for SJS/TEN and DRESS, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27156746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27156746'])">Ref</a></span>). In vancomycin-induced LABD, lesions typically appear 1 to 15 days after the first vancomycin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28168063','lexi-content-ref-9735094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28168063','lexi-content-ref-9735094'])">Ref</a></span>); a median latency of 7 days was observed in a systematic review (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27156746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27156746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with end-stage renal disease (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2139270','lexi-content-ref-31356340','lexi-content-ref-9399623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2139270','lexi-content-ref-31356340','lexi-content-ref-9399623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In DRESS, a strong association was observed for patients with the HLA-A*32:01 allele in a study involving predominantly European ancestry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30776417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30776417'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity with teicoplanin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22017186','lexi-content-ref-31722513','lexi-content-ref-27572807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22017186','lexi-content-ref-31722513','lexi-content-ref-27572807'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Systemic exposure is associated with <b>nephrotoxicity </b>(usually reversible), which may result in acute kidney injury (or <b>acute renal failure</b>), predominantly occurring in patients with multiple risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31904834','lexi-content-ref-25220436','lexi-content-ref-31369087','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31904834','lexi-content-ref-25220436','lexi-content-ref-31369087','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>). Cases of systemic absorption and nephrotoxicity with oral vancomycin have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19638004','lexi-content-ref-6703548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19638004','lexi-content-ref-6703548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; most commonly attributed to acute tubular necrosis (or <b>renal tubular necrosis</b>), resulting from direct oxidative stress on proximal tubule cells or obstructive tubular cast formation. In addition, acute<b> interstitial nephritis </b>has also been described, characterized by tubular and interstitial inflammation, resulting from an immunologically mediated (non-IgE) process (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31369087','lexi-content-ref-27156746','lexi-content-ref-21716699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31369087','lexi-content-ref-27156746','lexi-content-ref-21716699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually occurs 5 to 7 days and up to 14 days following monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22411630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22411630'])">Ref</a></span>). Acute interstitial nephritis was observed at a median onset of 26 days in a systematic case review (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27156746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27156746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Vancomycin exposure (trough levels ≥15 mg/L, larger AUC [&gt;650 to 1,300 mg-h/L], high daily doses [&gt;4 g/day]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy &gt;7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Critical illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nephrotoxin therapy or concurrent prolonged use of piperacillin/tazobactam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25220436','lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults &gt;65 years:</p>
<p style="text-indent:-2em;margin-left:8em;">• Parenteral: Less commonly associated risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22411630','lexi-content-ref-28474732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22411630','lexi-content-ref-28474732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Oral: Increases the risk of systemic absorption from oral vancomycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neutropenia/pancytopenia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia </b>(severe) and <b>agranulocytosis</b> have been observed in numerous case reports and case series; in some cases, <b>drug fever</b> also accompanied the neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21521866','lexi-content-ref-30174327','lexi-content-ref-12204187','lexi-content-ref-10030777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21521866','lexi-content-ref-30174327','lexi-content-ref-12204187','lexi-content-ref-10030777'])">Ref</a></span>). Reversible <b>pancytopenia </b>has also been reported in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Carmichael.1986','lexi-content-ref-27192600','lexi-content-ref-12204187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Carmichael.1986','lexi-content-ref-27192600','lexi-content-ref-12204187'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; available data suggest a peripheral mechanism mediated by antibodies and direct toxicity to the bone marrow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30174327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30174327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; usually occurs after 7 to 12 days of treatment, with most cases occurring after 20 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21521866','lexi-content-ref-30174327','lexi-content-ref-19843487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21521866','lexi-content-ref-30174327','lexi-content-ref-19843487'])">Ref</a></span>). However, 1 case report described an onset of 8 weeks following discontinuation of a 3-week course, and then upon rechallenge, neutropenia recurred 3 days following reinitiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22170976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22170976'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure (ie, &gt;7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21521866','lexi-content-ref-9391687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21521866','lexi-content-ref-9391687'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Teicoplanin: In patients experiencing neutropenia who were switched to teicoplanin (another glycopeptide), 50% of these patients also developed teicoplanin-induced neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19843487']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19843487'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ototoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Vancomycin is infrequently associated with <b>ototoxicity</b>, manifested as <b>tinnitus</b>, sensorineural <b>hearing loss</b>, <b>dizziness</b>, or <b>vertigo</b>; some cases have reported irreversible hearing loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19001107','lexi-content-ref-12503934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19001107','lexi-content-ref-12503934'])">Ref</a></span>). Of note, vancomycin has not been found to be ototoxic in animal models (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19106348','lexi-content-ref-2669623','lexi-content-ref-2294943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19106348','lexi-content-ref-2669623','lexi-content-ref-2294943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; proposed to be via direct damage to the auditory branch of the eighth cranial nerve, although data are conflicting and unclear if ototoxicity is directly attributable to vancomycin or to other confounding factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25753888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25753888'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19001107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19001107'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration with ototoxic agents (eg, aminoglycosides) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19001107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19001107'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3057327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3057327'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vancomycin infusion reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vancomycin infusion reaction</b>, a non-IgE-mediated drug reaction most often characterized by an erythematous rash, generalized <b>flushing,</b> and <b>pruritus, </b>may occur. Severe reactions, which are uncommon, may also include <b>hypotension, chest</b>
<b>pain, </b>and <b>dyspnea. </b>Rarely, vancomycin infusion reaction may be life-threatening and cause severe hypotension and cardiac arrest or cardiovascular collapse. Clinical presentation can be similar to IgE-mediated anaphylaxis making it difficult for clinicians to distinguish between the 2 reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33830710','lexi-content-ref-31123702','lexi-content-ref-32571794','lexi-content-ref-18710566','lexi-content-ref-24926475','lexi-content-ref-3971208','lexi-content-ref-29398192','lexi-content-ref-3986655','lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33830710','lexi-content-ref-31123702','lexi-content-ref-32571794','lexi-content-ref-18710566','lexi-content-ref-24926475','lexi-content-ref-3971208','lexi-content-ref-29398192','lexi-content-ref-3986655','lexi-content-ref-11724099'])">Ref</a></span>). Reactions usually cease promptly after infusion is stopped.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-IgE-mediated drug reaction caused by histamine release from mast cells and basophils found in the skin, lung, GI tract, myocardium, and vascular system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11724099'])">Ref</a></span>). The mast cell receptor MRGPRX2 has also been identified as a cause of non-IgE-mediated drug reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30072729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30072729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; usually occurs 4 to 10 minutes after the start of the infusion with the first dose but may also occur at any time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12720556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12720556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Typically caused by rapid IV infusion (&lt;1 hour) of large doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14570656','lexi-content-ref-12720556','lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14570656','lexi-content-ref-12720556','lexi-content-ref-11724099'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that also induce histamine release including ciprofloxacin; barbiturates; opioids (except fentanyl which rarely induces histamine); certain neuromuscular antagonists (atracurium, cisatracurium, doxacurium, mivacurium, succinylcholine, tubocurarine); propofol; plasma expanders (dextran, polygeline); and radiocontrast agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7687945','lexi-content-ref-12720556','lexi-content-ref-11724099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7687945','lexi-content-ref-12720556','lexi-content-ref-11724099'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F233298"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Chest pain, flushing, hypotension, shock, vasculitis</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Bullous dermatitis, erythema of skin, exfoliative dermatitis (Forrence 1990), pruritus, Stevens-Johnson syndrome (Lin 2014)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Agranulocytosis (di Fonzo 2018), eosinophilia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction (Kupstaite 2010)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection site phlebitis, irritation at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Chills, dizziness, malaise, vertigo</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Hearing loss (Klibanov 2003), ototoxicity (Forouzesh 2009), tinnitus (Traber 1981)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased blood urea nitrogen (Bergman 1988), increased serum creatinine, interstitial nephritis (Bergman 1988), renal tubular necrosis (Shah-Khan 2011)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Dyspnea, wheezing</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (Smith 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypersensitivity angiitis (Pingili 2017)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acute generalized exanthematous pustulosis (Mawri 2015), dermatologic disorder (linear IgA bullous dermatosis) (Tashima 2014), erythema multiforme (Khicher 2019), maculopapular rash (Marik 1997), toxic epidermal necrolysis (Changela 2013)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: <i>Clostridioides difficile</i> associated diarrhea (Hecht 1989), <i>Clostridioides difficile</i> colitis (Hecht 1989), peritonitis (following intraperitoneal administration during CAPD) (Freiman 1992)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Henoch-Schonlein purpura (Min 2017), immune thrombocytopenia (Al Jafar 2015; Mohammadi 2017), neutropenia (reversible) (literature suggests an incidence ranging from 2% to 12%) (Black 2011; di Fonzo 2018), pancytopenia (Carmichael 1986)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Anaphylaxis (Anne 1994), fixed drug eruption (Gilmore 2004), vancomycin infusion reaction (literature suggests an incidence ranging from 4% to as high as 47%) (Alvarez-Arango 2021; Austin 2020; Symons 1985; Wazny 2001)</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Cacoub 2011)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Acute kidney injury (Sawada 2018), nephrotoxicity (Lodise 2009)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Hypokalemia (13%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (15%), nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Peripheral edema (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Diarrhea (9%), flatulence (8%), vomiting (9%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary tract infection (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Fatigue (5%), headache (7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Back pain (6%)</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Nephrotoxicity (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Depression, insomnia</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased serum creatinine, renal failure syndrome, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Acute generalized exanthematous pustulosis, dermatologic disorder (linear IgA bullous dermatosis) (Tashima 2014), exfoliative dermatitis (Forrence 1990), pruritus, skin rash, Stevens-Johnson syndrome (An 2011), toxic epidermal necrolysis (An 2011), urticaria</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Eosinophilia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Anaphylaxis, flushing (Arroyo-Mercado 2019), nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:6em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Cacoub 2011)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Chills, dizziness, drug fever, pain, vertigo</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Muscle spasm (chest and back)</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Dyspnea, wheezing</p></div>
<div class="block coi drugH1Div" id="F233314"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to vancomycin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F233295"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation and thrombophlebitis: IV vancomycin is an irritant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Pain, tenderness, and necrosis may occur with extravasation. If thrombophlebitis occurs, slow infusion rates, dilute solution (eg, 2.5 to 5 g/L) and rotate infusion sites.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inflammatory bowel disease: Clinically significant serum concentrations have been reported in patients with inflammatory disorders of the intestinal mucosa who have taken oral vancomycin (multiple doses) for the treatment of <i>C. difficile</i>-associated diarrhea. Although use may be warranted, the risk for adverse reactions may be higher in this situation; consider monitoring serum trough concentrations in patients with renal insufficiency, severe colitis, and a prolonged course (IDSA/SHEA [McDonald 2018]; Pettit 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment or those receiving other nephrotoxic drugs; dosage modification required and close monitoring is recommended in patients with preexisting renal impairment and those at high risk for renal impairment. Accumulation may occur after multiple oral doses of vancomycin in patients with renal impairment; consider monitoring serum concentrations in this circumstance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Oral vancomycin is only indicated for the treatment of CDI or enterocolitis due to <i>S. aureus</i> and is not effective for systemic infections; parenteral vancomycin is not effective for the treatment of enterocolitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intraocular administration (off-label route): Hemorrhagic occlusive retinal vasculitis (HORV), including permanent visual loss, has been reported in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intraperitoneal administration (off-label route): Use caution when administering intraperitoneally (IP); in some continuous ambulatory peritoneal dialysis (CAPD) patients, chemical peritonitis (cloudy dialysate, fever, severe abdominal pain) has occurred. Symptoms are self-limited and usually clear after vancomycin discontinuation.</p></div>
<div class="block dosfc drugH1Div" id="F45040033"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">First-Vancomycin oral solution is a compounding kit. Refer to manufacturer’s labeling for compounding instructions.</p></div>
<div class="block foc drugH1Div" id="F233306"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vancocin: 125 mg, 250 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 750 mg/150 mL (150 mL); 1000 mg/200 mL (200 mL); 1250 mg/250 mL (250 mL); 1500 mg/300 mL (300 mL); 1750 mg/350 mL (350 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/100 mL (100 mL); 2000 mg/400 mL (400 mL); 1 g/200 mL in Dextrose 5% (200 mL); 1 g/200 mL in NaCl 0.9% (200 mL); 500 mg/100 mL in Dextrose 5% (100 mL); 750 mg/150 mL in Dextrose 5% (150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.25 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 1.5 g (1 ea); 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg (1 ea [DSC]); 500 mg (1 ea); 750 mg (1 ea); 1 g (1 ea); 1.5 g (1 ea); 5 g (1 ea); 10 g (1 ea); 100 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Firvanq: 25 mg/mL (150 mL, 300 mL); 50 mg/mL (150 mL, 300 mL) [contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10), sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Firvanq: 50 mg/mL (150 mL [DSC], 300 mL [DSC]) [contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10), sodium benzoate; white grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (150 mL, 300 mL); 50 mg/mL (150 mL, 300 mL); 250 mg/5 mL (80 mL, 150 mL, 300 mL)</p></div>
<div class="block geq drugH1Div" id="F233291"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F233317"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vancocin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $103.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $190.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vancomycin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $31.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $57.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vancomycin HCl in Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/200ML 5% (per mL): $0.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL 5% (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750MG/150ML 5% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vancomycin HCl in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/200ML 0.9% (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL 0.9% (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750MG/150ML 0.9% (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vancomycin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg/150 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/200 mL (per mL): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1250 mg/250 mL (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500MG/300ML (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1750MG/350ML (per mL): $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000MG/400ML (per mL): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Firvanq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $0.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $1.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Vancomycin HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $4.14 - $19.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 g (per each): $24.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 g (per each): $28.94 - $29.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 g (per each): $19.72 - $108.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $39.18 - $260.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 g (per each): $600.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $2.96 - $9.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $8.02 - $11.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Vancomycin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $0.83 - $0.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $1.09 - $1.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868570"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vancocin: 125 mg, 250 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/200 mL in NaCl 0.9% (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea, 10 mL); 1000 mg (1 ea); 1 g (1 ea, 20 mL, 30 mL); 5 g (1 ea); 10 g (1 ea)</p></div>
<div class="block exp drugH1Div" id="F14320792"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A vancomycin oral solution (25 mg/mL or 50 mg/mL) is commercially available (Firvanq).</p>
<p style="text-indent:0em;">
<b>Oral Solution</b></p>
<p style="text-indent:0em;">Using a vial of vancomycin powder for injection (reconstituted to 50 mg/mL), add the appropriate volume for the dose to 30 mL of water and administer orally or via NG tube. For oral administration, common flavoring syrups may be added to improve taste.</p>
<div class="reference">Vancomycin hydrochloride injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2018.</div>
<p style="text-indent:0em;margin-top:2em;">
<b>25 mg/mL Oral Solution</b></p>
<p style="text-indent:0em;">A vancomycin 25 mg/mL solution in Ora-Sweet and water (1:1) may be prepared by reconstituting vancomycin for injection with sterile water, then dilute with a 1:1 mixture of Ora-Sweet and distilled water to a final concentration of 25 mg/mL; transfer to amber prescription bottle. Stable for 75 days refrigerated or for 26 days at room temperature.</p>
<div class="reference">Ensom MH, Decarie D, and Lakhani A, “Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4°C and 25°C,” <i>Can J Hosp Pharm</i> 2010, 63(5):366-72.<span class="pubmed-id">22479004</span></div>
</div>
<div class="block admp drugH1Div" id="F52613999"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution (Firvanq): Shake reconstituted oral solution well before each use.</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for injection: Reconstituted powder for injection (not premixed solution) may be diluted and used for oral administration; common flavoring syrups may be added to improve taste. The unflavored, diluted solution may also be administered via nasogastric tube.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent: Administer intermittent IV infusion over 60 minutes. Vancomycin infusion reaction (formerly "red man syndrome") may occur if the infusion is too rapid. It is not an allergic reaction, but may be characterized by hypotension and/or a maculopapular rash appearing on the face, neck, trunk, and/or upper extremities; if this should occur, slow the infusion rate to administer dose over 90 to 120 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1693055','lexi-content-ref-PIDS.1','lexi-content-ref-8870903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1693055','lexi-content-ref-PIDS.1','lexi-content-ref-8870903'])">Ref</a></span>) and increase the dilution volume; the reaction usually dissipates in 30 to 60 minutes; administration of antihistamines just before the infusion may also prevent or minimize this reaction.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous: After loading dose, administer over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Girand.2019','lexi-content-ref-29718415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Girand.2019','lexi-content-ref-29718415'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Irritant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information varies regarding the use of dry cold or dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>); however, dry warm compresses may be of benefit in increasing local blood flow to enhance drug removal from the extravasation site. Intradermal hyaluronidase may be considered for refractory cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intrathecal/Intraventricular: Use preservative-free preparations only. Administer as diluted solution (1 to 10 mg/mL) over 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AL-Jeraisy.1','lexi-content-ref-19558257','lexi-content-ref-29067501','lexi-content-ref-9314470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AL-Jeraisy.1','lexi-content-ref-19558257','lexi-content-ref-29067501','lexi-content-ref-9314470'])">Ref</a></span>). When administered through a ventricular drain, clamp drain for 15 to 60 minutes to allow vancomycin solution to equilibrate in the cerebrospinal fluid (CSF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intracatheter (vascular); antibiotic lock technique: Instill prepared vancomycin lock solution into each lumen of the catheter access port using a volume sufficient to fill the catheter with a dwell time of ≥8 to 12 hours and up to 72 hours (dependent on frequency of catheter use). Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25548523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880743','lexi-content-ref-19489710','lexi-content-ref-25548523'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Instill vancomycin enema solution via rectal foley; retain for 1 hour. In pediatric patients the optimal doses have not been established; suggested volumes for pediatric patients: 1 to 3 years of age: 50 mL; 4 to 9 years of age: 75 mL; &gt;10 years of age: 100 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27062204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27062204'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F233311"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravenous:</b> Administer vancomycin with a final concentration not to exceed 5 mg/mL by IV intermittent infusion over at least 60 minutes (recommended infusion period of ≥30 minutes for every 500 mg administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19106348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19106348'])">Ref</a></span>)); in adult patients in need of fluid restriction, a concentration up to 10 mg/mL may be used, but risk of infusion-related reactions is increased. Not for IM administration.</p>
<p style="text-indent:-2em;margin-left:4em;">If a maculopapular rash appears on the face, neck, trunk, and/or upper extremities (vancomycin infusion reaction [formerly “red man syndrome”]), slow the infusion rate to over 1<sup>1</sup>/<sub>2</sub> to 2 hours and increase the dilution volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32571794','lexi-content-ref-1693055','lexi-content-ref-3769763','lexi-content-ref-8870903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32571794','lexi-content-ref-1693055','lexi-content-ref-3769763','lexi-content-ref-8870903'])">Ref</a></span>). Hypotension, shock, and cardiac arrest (rare) have also been reported with too rapid of infusion. Administration of antihistamines prior to infusion may prevent or minimize this reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3769763','lexi-content-ref-10488798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3769763','lexi-content-ref-10488798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity. Information conflicts regarding the use of dry cold or dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>); however, dry warm compresses may be of benefit in increasing local blood flow to enhance drug removal from the extravasation site. Hyaluronidase may be considered for refractory cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Antibiotic lock technique (off-label use):</b> Instill prepared vancomycin lock solution into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of 48 to 72 hours (dependent on frequency of catheter use). Withdraw lock solution prior to catheter use; replace with fresh vancomycin lock solution after catheter use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-17403700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-17403700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraventricular (off-label route):</b> Use preservative-free preparations only. May be administered intraventricularly with a final concentration of 2.5 to 10 mg/mL for the treatment of CSF shunt infections. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow vancomycin solution to equilibrate in the CSF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-23090839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777','lexi-content-ref-23090839'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravitreal (off-label route):</b> May administer vancomycin intravitreally with a final concentration of 1 mg/0.1 mL NS or sterile water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Durand.1','lexi-content-ref-7487614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Durand.1','lexi-content-ref-7487614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution (Firvanq): Shake reconstituted oral solution well before each use.</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Reconstituted powder for injection (not premixed solution) may be diluted and used for oral administration; common flavoring syrups may be added to improve taste. The unflavored, diluted solution may also be administered via nasogastric tube.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal (off-label route):</b> May be administered as a retention enema per rectum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29562266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29562266'])">Ref</a></span>); 500 mg in 100 to 500 mL of NS, volume may depend on length of segment being treated. If sodium chloride causes hyperchloremia could use solution with lower chloride concentration (eg, LR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439232'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F1671784"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Flexible bags: Store below 25°C (77°F) in the original package. Use within 28 days of removal from aluminum overpouch. Stable at room temperature for 28 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Galaxy containers: Store Galaxy containers at or below -20°C (-4°F). Handle frozen product containers with care; may be fragile in the frozen state. Thaw frozen containers at 25°C (77°F) or 5°C (41°F). Do not immerse in water bath or microwave. Thawed solution in remains chemically stable for 72 hours at 25°C (77°F) or for 30 days when stored at 5°C (41°F). Do not refreeze thawed antibiotics.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution (Firvanq): Store at 2°C to 8°C (36°F to 46°F) prior to and following reconstitution; discard reconstituted solution after 14 days or if appears hazy or contains particulates. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Vials: Store intact vials at 20°C to 25°C (68°F to 77°F). Reconstitute vial using an appropriate diluent; recommendations may vary by product; refer to manufacturer's labeling for choice of diluent and for appropriate storage conditions and timeframes. Prior to administration, further dilution in a compatible solution is required; recommendations may vary by product; refer to manufacturer's labeling for list of compatible solutions and appropriate storage conditions and timeframes.</p>
<p style="text-indent:-2em;margin-left:2em;">Pharmacy bulk packages: Store at 20°C to 25°C (68°F to 77°F). Discard pharmacy bulk packages no later than 4 hours after initial closure puncture.</p></div>
<div class="block usep drugH1Div" id="F53569424"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of patients with the following infections or conditions: Infections due to documented or suspected methicillin-resistant <i>Staphylococcus aureus</i> or beta-lactam resistant coagulase negative <i>Staphylococcus</i>; serious or life-threatening infections (eg, endocarditis, meningitis, osteomyelitis) due to documented or suspected staphylococcal or streptococcal infections in patients who are allergic to penicillins and/or cephalosporins; empiric therapy of infections associated with central lines, VP shunts, hemodialysis shunts, vascular grafts, prosthetic heart valves (FDA approved in all ages). Has also been used for prophylaxis of peritonitis in patients with peritoneal dialysis (PD) catheters undergoing invasive gastrointestinal procedure, touch contamination prophylaxis of PD catheter, and for the treatment of peritonitis in patients with peritoneal catheters.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of <i>Clostridioides</i>
<i>difficile</i> infection and treatment of enterocolitis caused by <i>S. aureus</i> (including methicillin-resistant strains) (All indications: FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block mst drugH1Div" id="F233387"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IV vancomycin may be confused with INVanz</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vancomycin may be confused with clindamycin, gentamicin, tobramycin, valACYclovir, vecuronium, Vibramycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300205"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F233300"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Vancomycin may enhance the nephrotoxic effect of Aminoglycosides. Vancomycin may enhance the neurotoxic effect of Aminoglycosides.  Management: Consider avoiding coadministration of aminoglycosides and vancomycin unless clinically indicated. If coadministered, monitor closely for signs of nephrotoxicity and neurotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Vancomycin may enhance the nephrotoxic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cloxacillin: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Vancomycin may enhance the nephrotoxic effect of Colistimethate.  Management: Avoid coadministration of colistimethate and vancomycin whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Vancomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Vancomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperacillin: May enhance the nephrotoxic effect of Vancomycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurolidine: Vancomycin may diminish the therapeutic effect of Taurolidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F233319"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F52879178"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy status should be evaluated in patients who may become pregnant prior to using the IV formulation containing the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA).</p></div>
<div class="block pri drugH1Div" id="F6833811"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Vancomycin crosses the placenta and can be detected in fetal serum, amniotic fluid, and cord blood (Bourget 1991; Reyes 1989). Adverse fetal effects, including sensorineural hearing loss or nephrotoxicity, have not been reported following maternal use during the second or third trimesters of pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of vancomycin may be altered during pregnancy and pregnant patients may need a higher dose of vancomycin. Maternal half-life is unchanged, but the volume of distribution and the total plasma clearance may be increased (Bourget 1991). Individualization of therapy through serum concentration monitoring may be warranted.</p>
<p style="text-indent:0em;margin-top:2em;">Vancomycin is recommended for the treatment of mild, moderate, or severe <i>Clostridioides difficile</i> infections in pregnant patients. Standard doses should be used (ACG [Surawicz 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Vancomycin is recommended as an alternative option to prevent the transmission of group B streptococcal (GBS) disease from mothers to newborns. Untreated asymptomatic GBS disease can result in maternal urinary tract infection, intraamniotic infection, endometritis, preterm labor, and/or stillbirth. Vertical transmission from the mother can cause sepsis, pneumonia, or meningitis in the newborn. Vancomycin IV is recommended for use in women who are at high risk for anaphylaxis to penicillin (or whose risk is unknown), and the GBS isolate is resistant to clindamycin. Dose and rate of infusion should be based on maternal weight and renal function, similar to nonpregnant patients (ACOG 2020).</p>
<p style="text-indent:0em;margin-top:2em;">In patients known to be colonized with methicillin-resistant <i>S. aureus</i> (MRSA), a single dose of vancomycin is recommended as part of the antibiotic regimen for prophylactic use prior to cesarean delivery. Monotherapy with vancomycin does not provide sufficient coverage for cesarean delivery surgical prophylaxis (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Based on limited data, vancomycin is considered likely compatible with pregnancy when used for the treatment of airway diseases, such as cystic fibrosis (ERS/TSANZ [Middleton 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">The formulation of vancomycin injection containing the excipients polyethylene glycol (PEG 400) and N-acetyl D-alanine (NADA) has caused fetal malformations in animal reproduction studies. If use of vancomycin is needed during the first or second trimesters of pregnancy, use other available formulations of vancomycin.</p></div>
<div class="block mopp drugH1Div" id="F53569415"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function tests (eg, BUN, SCr, urine output), serum vancomycin concentrations (See "Reference Range"), WBC; hearing test (especially in patients receiving concurrent ototoxic agents); fluid status. Monitor for vancomycin infusion reaction during administration.</p></div>
<div class="block rerp drugH1Div" id="F53568993"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>AUC-based monitoring</b> (ASHP/IDSA/PIDS/SIDP [Rybak 2020]): <b>Note: </b>Evaluate vancomycin exposure using area under the curve over 24 hours (AUC<sub>24</sub>). AUC can be determined in neonatal and pediatric patients using either a neonatal- or pediatric-specific Bayesian software program with 1 or 2 concentrations (ie, trough only or peak and random or trough) or standard first-order pharmacokinetic equations using 2 vancomycin concentrations. AUC<sub>24</sub> should be ≤800 mg•hour/L to minimize risk of nephrotoxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Staphylococcus aureus </i>target: AUC<sub>24</sub>:MIC: 400; potentially up to 600.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Target for <i>S. aureus</i> is based on an MIC determined by broth microdilution (BMD); it is recommended to assume a minimum inhibitory concentration (MIC) of 1 mg/L, unless MIC is demonstrated to be &gt;1 mg/L by BMD. Decreasing the dose when MIC &lt;1 mg/L by BMD is not recommended. AUC<sub>24</sub> should be ≤800 mg•hour/L and trough concentration ≤15 mg/L to minimize risk of nephrotoxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">Coagulase-negative staphylococci target: Neonates and infants ≤3 months of age (targets associated with bacteremia bacteriological cure): AUC<sub>24</sub> ≥300 mg•hour/L in first 24 hours of therapy or AUC<sub>24</sub> ≥424 mg•hour/L in the second 24 hours of therapy (Gwee 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Trough-based monitoring: Note: </b>Trough concentrations ≥15 mg/L have been associated with increased risk for acute kidney injury, likely due to association with elevated AUCs (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Coagulase-negative staphylococci</i>: Neonates: Trough concentrations 5 to 15 mg/L have been suggested based on limited data for AUC targets (Frymoyer 2019); however, AUC monitoring may be preferred (Gwee 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Endocarditis: </i>10 to 15 mg/L; may target higher trough of 15 to 20 mg/L in patients with methicillin-resistant <i>S. aureus </i>(MRSA) with MIC &gt;1 mg/L or who are not responding to appropriate therapy (AHA [Baltimore 2015]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Meningitis, including health care-associated ventriculitis/meningitis: </i>15 to 20 mg/L (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>MRSA infections:</i> Though trough-only monitoring is not recommended for serious infections, trough serum concentration might be used as a surrogate marker for AUC when AUC monitoring is not available or for less serious infections; trough concentrations may not accurately predict AUC on an individual level (ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Frymoyer 2014; Stockmann 2015).</p>
<p style="text-indent:-2em;margin-left:8em;">Neonates: Trough concentrations of 8 to 15 mg/L have been associated with AUCs of ≥400 mg•hour/L (ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Frymoyer 2014; Gwee 2019; Gwee 2022; Mulubwa 2020; Stockmann 2015; Tseng 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Trough concentrations of 7 to 10 mg/L have been associated with AUCs &gt;400 mg•hour/L; significant variability observed; lower trough concentrations (ie, 6 mg/L) may be associated with AUC &gt;400 mg•hour/L when dose is divided every 8 hours (Frymoyer 2013; Le 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Target steady-state concentration:</i> Optimal target unknown.</p>
<p style="text-indent:-2em;margin-left:8em;">General reported range: 15 to 30 mg/L; a variety of target concentrations have been reported in pediatric patients (Cies 2016; Genuini 2018; Guilhaumou 2016; Hurst 2019; McKamy 2012).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Treatment of MRSA: 20 to 25 mg/L is recommended in adults. AUC<sub>24</sub> can be estimated by multiplying the steady-state concentration by 24; a target steady-state concentration of 20 to 25 mg/L equates to an AUC<sub>24</sub> of 480 to 600 mg•hour/L (ie, a steady-state concentration of ≥16.7 mg/L would equate to an AUC<sub>24</sub> of ≥400 mg•hour/L) (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Timing of serum sampling:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>AUC</i>: Monitoring may begin within 24 to 48 hours of drug initiation; Bayesian-derived AUC calculation programs do not require steady-state serum concentrations. First-order pharmacokinetic analytic equations to estimate AUC require collection of 2 serum concentrations; postdistributional peak concentration (C<sub>max</sub>) drawn 1 to 2 hours after infusion and trough concentration (C<sub>min</sub>) drawn at the end of the dosing interval. It is preferable that a near steady-state postdistributional peak and trough concentration within the same dosing interval (if possible) are used with the equation-based method. For Bayesian monitoring, 1 (ie, trough only) or 2 concentrations may be used. (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Trough monitoring</i>: Draw trough concentration just before the administration of a dose, at the end of the dosing interval, at steady-state conditions. Steady-state conditions generally occur approximately after the third dose; therefore, may begin monitoring vancomycin trough concentrations before the fourth dose (usually within 1 hour of administration). (ASHP/IDSA/SIDP [Rybak 2009]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion monitoring</i>: Obtain after steady-state has been reached, ≥24 hours after initiation of infusion; may obtain sooner if Bayesian-derived program is utilized (Berthaud 2019; Hurst 2019; McKamy 2012). Ensure that sample is obtained from a separate line or site than that through which vancomycin is infused; obtaining from the same line, even a separate lumen, or stopping the infusion is not recommended (Hurst 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Frequency of serum sampling:</b> Should be based on clinical judgment; close monitoring (more frequent or daily) recommended for hemodynamically unstable patients, patients with renal dysfunction, and patients with potential augmented renal clearance; hemodynamically stable patients may be monitored less frequently (once weekly) (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral/rectal therapy:</b> Serum sample monitoring is not typically required; systemic absorption of enteral vancomycin may occur in patients with mucosal disruption due to colitis, especially in patients with renal failure. Monitoring serum vancomycin levels may be considered for patients with renal failure who have severe colitis and require a prolonged course of enteral vancomycin (IDSA/SHEA [McDonald 2018]; Pettit 2015).</p></div>
<div class="block pha drugH1Div" id="F233294"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by blocking glycopeptide polymerization through binding tightly to D-alanyl-D-alanine portion of cell wall precursor</p></div>
<div class="block phk drugH1Div" id="F233313"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Poor; Rectal: significant absorption through inflamed colonic mucosa may occur; Intraperitoneal (IP): 60% of an IP dose absorbed in 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes widely in body tissue and fluids, except for cerebrospinal fluid (CSF).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates, term: 0.57 to 0.69 L/kg (de Hoog 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: 0.56 L/kg (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤6 years of age: 0.61 L/kg (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;6 years of age: 0.47 L/kg (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 0.49 L/kg (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.4 to 1 L/kg (ASHP/IDSA/SIDP [Rybak 2009]); 0.3 to 0.5 L/kg in patients who are morbidly obese (Adane 2015; Bauer 1998; Hong 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Relative diffusion from blood into CSF: Good only with inflammation (exceeds usual MICs).</p>
<p style="text-indent:-2em;margin-left:6em;">Children:</p>
<p style="text-indent:-2em;margin-left:8em;">CSF concentrations: 0.2 to 17.3 mg/L (de Hoog 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">CSF:blood level ratio: Normal meninges: Nil; Inflamed meninges: 7.1% to 68% (de Hoog 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults:</p>
<p style="text-indent:-2em;margin-left:8em;">Uninflamed meninges: 0 to 4 mg/L; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009]).</p>
<p style="text-indent:-2em;margin-left:8em;">Inflamed meninges: 6 to 11 mg/L; serum concentration dependent (ASHP/IDSA/SIDP [Rybak 2009]).</p>
<p style="text-indent:-2em;margin-left:8em;">CSF:serum level ratio: Normal meninges: Nil; Inflamed meninges: ~80% (Shokouhi 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~55%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: No apparent metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Biphasic: Terminal:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates (GA: 32 to 34 weeks); PNA ~3 to 5 days: 5.9 to 9.8 hours (Schaad 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates; PNA ~2 to 3 days: 6.7 hours (Schaad 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 2.8 hours (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years of age: 2.4 hours (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years of age: 2.9 hours (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 3.2 hours (Rainkie 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 4 to 6 hours; significantly prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: 7.5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IV: Immediately after completion of infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily via glomerular filtration; IV: Urine (75% as unchanged drug in the first 24 hours); Oral: Primarily feces.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: presence of malignancy in children is associated with an increase in vancomycin clearance.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 0.63 to 1.5 mL/minute/kg; dependent on GA and/or PMA (de Hoog 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients: Median: 1.1 mL/minute/kg (range: 0.33 to 1.87 mL/minute/kg) (Marsot 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 1.6 to 6.2 L/hour (Matzke 1984); patients who are obese: ~6 L/hour (rarely exceeds 9 L/hour) (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p></div>
<div class="block phksp drugH1Div" id="F51204421"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Extracorporeal membrane oxygenation (ECMO): Reported pharmacokinetic parameters in pediatric patients receiving ECMO vary widely based on ECMO circuitry/filters, age, weight, kidney function, and underlying diseases. In general, volume of distribution may be increased and clearance may be increased or decreased; reported parameters vary significantly; elimination half-life appears to be dependent upon renal function (Amaker 1996; Buck 1998; Cies 2017; Moffett 2018; Mulla 2005; Zylbersztajn 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total systemic and renal clearance may be reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy</i>: <b>Note: </b>Ratios, including the minimum inhibitory concentration (MIC), depend upon the methodology used; MIC determined by E-test is typically 1.5 to 2 times MIC determined by broth microdilution (ASHP/IDSA/PIDS/SIDP [Rybak 2020]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Staphylococcus aureus:</i> AUC/MIC<sub>BMD</sub> ≥400 mg•hour/L (ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Kullar 2011; Lodise 2014; Moise-Broder 2004); specific cutoff for efficacy has varied slightly between studies.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Enterococcus</i> spp.: AUC/MIC<sub>Etest</sub> ≥389 (Jumah 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Coagulase-negative staphylococci (neonates): </i>AUC<sub>24</sub> ≥300 mg•hour/L in first 24 hours of therapy or AUC<sub>24</sub> ≥424 mg•hour/L in the second 24 hours of therapy (Gwee 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Nephrotoxicity: AUC ≥600 to 650 mg•hour/L (adults); ≥800 mg•hour/L (pediatrics); risk continues to increase along AUC continuum (Aljefri 2019; ASHP/IDSA/PIDS/SIDP [Rybak 2020]; Fiorito 2018; Le 2015; Lodise 2020); C<sub>min</sub> ≥15 mg/L (ASHP/IDSA/PIDS/SIDP [Rybak 2020]; van Hal 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> A short postantibiotic effect has been observed in <i>E. faecalis</i> (0.5 to 1 hour) and <i>S. aureus</i> (0.6 to 2 hours); slightly longer in <i>S. epidermidis</i> (4.3 to 6.5 hours) (Hanberger 1991; Löwdin 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233320"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cinavan | Vancocin | Vancolon | Vancomicina | Vancomycin | Vancomycin HCL | Vantico</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rivervan | Vancocin | Vancoled | Vancomicina | Vancomicina fabra | Vancomicina filaxis | Vancomicina northia | Vancotenk | Varedet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Vancomycin | Vancomycin Abbott | Vancomycin alpharma | Vancomycin AptaPharma | Vancomycin Astro | Vancomycin eberth | Vancomycin eli lilly | Vancomycin hikma | Vancomycin mip | Vancomycin pfizer</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dbl vancomycin | Vancocin | Vancomycin | Vancomycin alphapharm | Vancomycin an | Vancomycin bnm | Vancomycin comp | Vancomycin sandoz | Vancomycin viatris | Vycin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Vancin | Vancobac | Vancomin | Vanmycin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Norimko | Vamysin | Vancocin | Vancomycin actavis | Vancomycin aurobindo | Vancomycine Billev pharma | Vancomycine bristol-m. squibb | Vancomycine fresenius kabi | Vancomycine mayne pharma (ben) | Vancomycine mylan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Acviscin | Edicin | Vancocin | Vancomycin | Vancomycin mip</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Celovan | Cloridrato de vancomicina | Hicovan | Novamicin | Vanclomin | Vancocid | Vancocina | Vancocina cp | Vancomicina | Vancoson</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancomycin fairmed | Vancomycin labatec | Vancomycin pfizer | Vancomycin sandoz</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Edicin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kovan | Vancomicina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fang ke lin | Hai zheng mei neng | Lai ke xin | Vancocin | Vancocin cp | Vanconal | Vancorin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alvanco | Enterocaps | Injovan | Sumicina | Tancofeto | Vanaurus | Vanbiotic | Vancocin cp | Vancocina hcl | Vancomicina | Vancomicina clorhidrato | Vancosala | Vaneotik | Vanoxat | Varedet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Lyphocin | Vancocin | Vancoled | Vancomycin actavis | Vancomycin AptaPharma | Vancomycin hikma | Vancomycin Kabi | Vancomycin mylan | Vancomycin Pharmaswiss | Vankomycin Pfizer</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ab vancomycin | Vanco | Vanco 500 ar | Vanco cell | Vanco saar | Vancomycin | Vancomycin Abbott | Vancomycin Enterocaps | Vancomycin Kabi | Vancomycin lyomark | Vancomycin noridem | Vancomycin Ratiopharm | Vancosan</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Vancomycin alpharma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Valepta | Vanaurus | Vancocina cp | Vancomicina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Vancomicina | Vancomicina richet | Varedet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocin | Vancomycin | Vancomycin Kabi | Vancomycin sandoz | Vancomycin teva | Vancosan | Vanmixan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocin cp | Vancogut | Vancolon | Vancomix | Vancomycin | Vetovancin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Diatracin | Vancomicina abbott | Vancomicina chiesi | Vancomicina Combino Pharm | Vancomicina normon | Vancomicina Pfizer | Vancomicina Sandoz</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Vancolon | Vancomycin | Vancomycin aurobindo | Vancomycin sala | Vancoten | Vansafe | Vansafe cp</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Orivan | Vancocin | Vancomycin Abbott | Vancomycin alpharma | Vancomycin orion | Vancomycin strides | Vancomycin xellia | Vancosan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Vancocine | Vancomycine dakota | Vancomycine kabi | Vancomycine lilly | Vancomycine merck | Vancomycine Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancomycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vancomycin | Vancomycin HCL | Vancomycin Kabi | Vancomycin/generics | Vancomycin/noridem | Vancomycin/Norma | Vancomycin/Vianex | Vancomycin/Vocate | Vancoten | Voncon | Vondem | Voxin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancoled | Vancomycin | Vancotex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancomycin Kabi | Vankomicin Pharmaswiss</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vanco ratiopharm | Vancoled | Vancomicina normon | Vancomycin | Vancomycin actavis | Vancomycin AptaPharma | Vancomycin human | Vancomycin Kabi | Vancomycin-b</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ledervan | Vancep | Vancocin | Vancodex | Vancomycin | Vancosan | Vantocil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancomycin | Vancomycin mylan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Vancoavenir</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Celovan | Cp van | Cytovan | E staph | Forstaf | G vanc | Ledovanc | Vanco-l | Vancocin | Vancocin cp | Vancogen | Vancogram | Vancoled | Vancolym | Vancomate | Vancomycin | Vancopil | Vancorid CP | Vancorin | Vancosa | Vancotech cp | Vancotroy | Vancowar cp | Vanking | Vanlid | Vansafe cp | Vantox cp | Venbruta | Vmycin</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Voxin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Copovan | Farmaciclin | Levovanox | Maxivanil | Vancocina | Vancomicina actavis | Vancomicina kabi | Vancomicina mylan | Zengac</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Tq vanc | Vanco | Vancolon | Vancomycin | Vinkamine | Zermacin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Solrein | Storacin | Vancomycin HCL | Vancomycin hcl shionogi | Vancomycin hydrochloride Hospira | Vancomycin hydrochloride merck hoei | Vancomycin Hydrochloride Sandoz | Vancomycin hydrochloride Sawai | Vancomycin hydrochloride Taiyo | Vancomycin kobayashi | Vancomycin meiji | Vanmycin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Vanbact | Vanco | Vancocin cp | Vancolon | Vancomicina azevedos | Vancomycin hikma | Vinkamine | Zermacin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Allvanco | Auskovancomycin | Daewoong vancomycin | Dong a vacomycin hydrochloride | Hanomycin | Inno.n vancomycin hcl | Kukje vancomycin hcl | Medica vancomycin hydrochloride | Pfizer vancomycin | Samsung vancomycin hci | Union vancomycin | Vanco kit | Vancocin cp | Vancoled | Vancomycin | Vancomycin hcl korea united | Vancostacin | Vancotreacin | Vancotrin | Vancozin | Varicin | Yooyoung vancomycin hcl</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancolon | Vancomycin | Voxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Vanco | Vancocin | Vancolon | Vancomycin labatec | Vancomycin sandoz | Vancomycine | Vancomycine mylan | Voxin | Zermacin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocin | Vancomycin | Vancomycin cnp | Vancomycin dr. eberth | Vancomycin Kabi | Vancomycin mylan | Vancomycin teva | Vancosan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Vancocin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocin | Vancomycin | Vancomycin Kabi | Vancomycin sandoz | Vancomycin teva | Vancosan | Vancotev | Vanmixan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Vancocine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alvarcin | Citerin | Estafimac | Estavam | Loricer | Vacsol | Valcidem | Vanaurus | Vancam | Vancocin | Vancocin cp | Vancomicina | Vancomicina gi | Vancomicina gi lem | Vancomicina gi pre | Vancomicina Probifasa | Vancox | Varamyn | Yectafhal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Celovan | Dhacocin | Tancofeto | Vancocin cp | Vancoled | Vancomycin | Vancomycin lyomark | Vancorin | Vancotex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Vancomycin sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancomycine | Vancomycine hikma | Vancomycine PCH | Vancomycine Sandoz | Vancomycine strides</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancocin matrigel | Vancomycin | Vancomycin axellia | Vancomycin strides | Vancomycin xellia</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lyphocin | Vancocin cp</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Celovan | Vancobiotic | Vancocina | Vancokem | Vancoliph | Vancomed | Vancomek | Vancomicina | Vancomicina cp | Vanconex | Vanconor | Vancoran | Vancotech cp</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Avancomycin | Imvaco | Labvacom | Mersa | Univan | Vancin | Vancocin cp | Vancokem | Vancolon | Vancomet | Vancomycin | Vancorest | Vancowell | Vanosyn | Varsa | Vencusin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Myvan | Vactrox | Vanbact | Vancare | Vanco | Vancocin | Vancocin cp | Vancolon | Vancom | Vancomark | Vancomycin | Vancosol | Vancotech | Vancotic | Vancowrd | Vanmycin | Vanqid | Vanzy | Vecocin | Vinjec | Zengac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Acviscin | Edicin | Lyphocin | Vancocin | Vancoled | Vancomycin HCL | Vancomycin Kabi | Vancotex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">First vancomycin | Firvanq | Vancocin | Vancoled | Vancomycin | Vancomycin HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Glipep i p | Vancocina cp | Vancomicina actavis | Vancomicina azevedos | Vancomicina billev | Vancomicina combino | Vancomicina generis | Vancomicina hikma | Vancomicina kabi | Vancomicina labesfal | Vancomicina normon | Vancomicina Pfizer</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Biomicine | Decamil | Vancap | Vancocin | Vancomax | Vancomicina abbott | Vancomicina dallas | Vancomicina dutriec | Vancomicina klonal | Vancomicina libra | Vancomicina nothia | Vancomicina quimfa | Vancomicina richet | Vancotie | Varedet</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Vanco | Vancolon | Vancomax | Vancopol | Vantox-CP | Vinkamine | Zermacin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Levovanox | Vancocin | Vancoled | Vancomicina | Vancomicina actavis | Vancomicina kabi | Vancomicina pharmaswiss | Vancomicina rompharm | Vancomycin teva | Vancotek</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancobact | Vancocin | Vancoled | Vancomabol | Vancomycin | Vancomycin j | Vancomycin teva | Vancorus | Vancosin | Vanmixan | Vero vancomycin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Colat | Tostaf | Vanco | Vancocin | Vancolon | Vancomycin | Vancomycin alphapharma | Vancomycin HCL | Vancomycin mylan | Vanin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vancocin | Vancomycin actavis | Vancomycin alpharma | Vancomycin Hospira | Vancomycin mip | Vancomycin Norcox | Vancomycin orion | Vancomycin sandoz | Vancomycin strides | Vancomycin Tika | Vancomycin xellia | Vancoscand</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dhacocin | Vancomycin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocyn CP | Vankomicin apta | Vankomicin kabi | Vankomicin mylan | Vankomicin Pfizer | Vankomicin Pharmaswiss</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Vancocin | Vancoled | Vancomycin Kabi | Vancomycin mip | Vancomycin mylan | Vancomycin Pharmaswiss | Vankomycin Actavis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Celovan | Edicin | G vanc | Vancin S | Vancocid | Vancocin cp | Vancogen | Vancolon | Vancomycin | Vancomycin Abbott | Vancomycin dbl | Vancomycin fujisawa</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vancomed | Vancomycin | Vancomycine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anko L | Edicin | Vamycin | Vancocin cp | Vancomax | Vancomycin HCL | Vancorin | Vancotek | Vankopol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">U-Vanco | Vanco | Vancocin cp | Vancomycin | Vancomycin cyh | Vanlyo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Edicin | Licovanum | Vanco | Vancocin | Vancogen | Vancomek | Vancomycin pharmex | Vancomycin vista | Vancomycinum | Vancotex | Vancovan | Vancum | Vanmixan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Vanbact | Vancolon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rivervan | Vancomicina | Vancomicina Eron | Vancomicina northia | Varedet</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vagram | Vanbiotic | Vancina | Vancobehr | Vancocyn | Vancoled | Vancomicina | Vancowell | Vanlid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen Vancomycin | Comavyn | Cytovan | Mylan Vancomycin | Vancocin cp | Vancomycin | Vancomycine fauldin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Vancocin cp</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Vancomycin HCL</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25644478">
<a name="25644478"></a>Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed <i>Staphylococcus aureus</i> infections. <i>Pharmacotherapy</i>. 2015;35(2):127-139. doi:10.1002/phar.1531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25644478/pubmed" id="25644478" target="_blank">25644478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26266247">
<a name="26266247"></a>Al-Jafar H, Al-Yousef A, Al-Shatti S, Al-Banwan K. Drug-immune thrombocytopenia with thrombosis versus heparin-induced thrombocytopenia: a critical clinical controversy. <i>Case Rep Nephrol Dial</i>. 2015;5(2):152‐159. doi:10.1159/000435806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26266247/pubmed" id="26266247" target="_blank">26266247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30715208">
<a name="30715208"></a>Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. <i>Clin Infect Dis.</i> 2019;69(11):1881-1887. doi:10.1093/cid/ciz051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30715208/pubmed" id="30715208" target="_blank">30715208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AL-Jeraisy.1">
<a name="AL-Jeraisy.1"></a>Al-Jeraisy M, Phelps SJ, Christensen ML, Einhaus S. Intraventricular vancomycin in pediatric patients with cerebrospinal fluid shunt infections. <i>J Pediatr Pharmacol Ther</i>. 2004;9(1):36-42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26856841">
<a name="26856841"></a>Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J. Optimizing the clinical use of vancomycin. <i>Antimicrob Agents Chemother</i>. 2016;60(5):2601-2609. doi: 10.1128/AAC.03147-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26856841/pubmed" id="26856841" target="_blank">26856841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33830710">
<a name="33830710"></a>Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin infusion reaction - moving beyond "Red Man Syndrome". <i>N Engl J Med</i>. 2021;384(14):1283-1286. doi:10.1056/NEJMp2031891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/33830710/pubmed" id="33830710" target="_blank">33830710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8723454">
<a name="8723454"></a>Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of Vancomycin in Critically Ill Infants Undergoing Extracorporeal Membrane Oxygenation. <i>Antimicrob Agents Chemother.</i> 1996;40(5):1139-1142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8723454/pubmed" id="8723454" target="_blank">8723454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett E, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3368290">
<a name="3368290"></a>American Academy of Pediatrics Committee on Infectious Diseases. Treatment of bacterial meningitis. <i>Pediatrics.</i> 1988;81(6):904-907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3368290/pubmed" id="3368290" target="_blank">3368290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018;132(3):e103-e119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31977795">
<a name="31977795"></a>American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion, number 797 [published correction appears in <i>Obstet Gynecol</i>. 2020;135(4):978-979]. <i>Obstet Gynecol</i>. 2020;135(2):e51-e72. doi:10.1097/AOG.0000000000003668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31977795/pubmed" id="31977795" target="_blank">31977795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15699079">
<a name="15699079"></a>American Thoracic Society and Infectious Diseases Society of America, "Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia," <i>Am J Respir Crit Care Med</i>, 2005, 171(4):388-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15699079/pubmed" id="15699079" target="_blank">15699079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32296501">
<a name="32296501"></a>An SH, Lee EM, Kim JY, Gwak HS. Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. <i>Eur J Hosp Pharm</i>. 2020;27(e1):e25-e29. doi:10.1136/ejhpharm-2018-001720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32296501/pubmed" id="32296501" target="_blank">32296501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21738885">
<a name="21738885"></a>An SY, Hwang EK, Kim JH, et al. Vancomycin-associated spontaneous cutaneous adverse drug reactions. <i>Allergy Asthma Immunol Res</i>. 2011;3(3):194‐198. doi:10.4168/aair.2011.3.3.194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21738885/pubmed" id="21738885" target="_blank">21738885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24799638">
<a name="24799638"></a>Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. <i>Infect Control Hosp Epidemiol</i>. 2014;35(6):605-627. doi: 10.1086/676022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24799638/pubmed" id="24799638" target="_blank">24799638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anderson.2020">
<a name="Anderson.2020"></a>Anderson DJ, Sexton DJ. Antimicrobial prophylaxis for prevention of surgical site infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7978531">
<a name="7978531"></a>Anne S, Middleton E Jr, Reisman RE. Vancomycin anaphylaxis and successful desensitization. <i>Ann Allergy</i>. 1994;73(5):402‐404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7978531/pubmed" id="7978531" target="_blank">7978531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12203166">
<a name="12203166"></a>Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe <i>Clostridium difficile</i> colitis: case series and review of the literature. <i>Clin Infect Dis</i>. 2002;35(6):690-696. doi:10.1086/342334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12203166/pubmed" id="12203166" target="_blank">12203166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31904834">
<a name="31904834"></a>Arnaud FCS, Libório AB. Attributable nephrotoxicity of vancomycin in critically ill patients: a marginal structural model study. <i>J Antimicrob Chemother</i>. 2020;75(4):1031‐1037. doi:10.1093/jac/dkz520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31904834/pubmed" id="31904834" target="_blank">31904834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23845922">
<a name="23845922"></a>Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. <i>Transfus Med Rev</i>. 2013;27(3):137‐145. doi:10.1016/j.tmrv.2013.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23845922/pubmed" id="23845922" target="_blank">23845922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31123702">
<a name="31123702"></a>Arroyo-Mercado F, Khudyakov A, Chawla GS, Cantres-Fonseca O, McFarlane IM. Red man syndrome with oral vancomycin: a case report. <i>Am J Med Case Rep</i>. 2019;7(1):16‐17. doi:10.12691/ajmcr-7-1-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31123702/pubmed" id="31123702" target="_blank">31123702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687133">
<a name="17687133"></a>Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. <i>N Engl J Med</i>. 2007;357(6):580‐587. doi:10.1056/NEJMra066469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/17687133/pubmed" id="17687133" target="_blank">17687133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32571794">
<a name="32571794"></a>Austin JP, Foster BA, Empey A. Replace red man syndrome with vancomycin flushing reaction. <i>Hosp Pediatr</i>. 2020;10(7):623-624. doi:10.1542/hpeds.2020-0125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32571794/pubmed" id="32571794" target="_blank">32571794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15956145">
<a name="15956145"></a>Baddour LM, Wilson WR, Bayer AS, et al, “Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary: <i>Endorsed by the Infectious Diseases Society of America</i>,” <i>Circulation</i>, 2005, 111(23):3167-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15956145/pubmed" id="15956145" target="_blank">15956145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18710566">
<a name="18710566"></a>Bailey P, Gray H. An elderly woman with 'red man syndrome' in association with oral vancomycin therapy: a case report. <i>Cases J</i>. 2008;1(1):111. doi:10.1186/1757-1626-1-111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/18710566/pubmed" id="18710566" target="_blank">18710566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3057327">
<a name="3057327"></a>Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. <i>Med Toxicol Adverse Drug Exp</i>. 1988;3(5):376‐386. doi:10.1007/BF03259891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3057327/pubmed" id="3057327" target="_blank">3057327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baker.1">
<a name="Baker.1"></a>Baker CJ. Prevention of early-onset group B streptococcal disease in neonates. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25475123">
<a name="25475123"></a>Baptista JP, Roberts JA, Sousa E, Freitas R, Deveza N, Pimentel J. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. <i>Crit Care.</i> 2014;18(6):654. doi:10.1186/s13054-014-0654-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25475123/pubmed" id="25475123" target="_blank">25475123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25675426">
<a name="25675426"></a>Bateman DA, Thomas W, Parravicini E, Polesana E, Locatelli C, Lorenz JM. Serum creatinine concentration in very-low-birth-weight infants from birth to 34-36 wk postmenstrual age. <i>Pediatr Res</i>. 2015;77(5):696-702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25675426/pubmed" id="25675426" target="_blank">25675426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9860149">
<a name="9860149"></a>Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. <i>Eur J Clin Pharmacol.</i> 1998;54(8):621-625. doi:10.1007/s002280050524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9860149/pubmed" id="9860149" target="_blank">9860149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973‐992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Benner KW, Worthington MA, Kimberlin DW, et al, "Correlation of Vancomycin Dosing to Serum Concentrations in Pediatric Patients: A Retrospective Database Review," <i>J Pediatr Pharmacol Ther</i>, 2009, 14:86-93.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055895">
<a name="23055895"></a>Benner KW, Worthington MA, Kimberlin DW, Hill K, Buckley K, Tofil NM. Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review. <i>J Pediatr Pharmacol Ther</i>. 2009;14(2):86-93. doi: 10.5863/1551-6776-14.2.86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23055895/pubmed" id="23055895" target="_blank">23055895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3178372">
<a name="3178372"></a>Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis associated with vancomycin therapy. <i>Arch Intern Med</i>. 1988;148(10):2139‐2140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3178372/pubmed" id="3178372" target="_blank">3178372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg</i>. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31591117">
<a name="31591117"></a>Berthaud R, Benaboud S, Hirt D, et al. Early Bayesian dose adjustment of vancomycin continuous infusion in children: a randomized controlled trial. <i>Antimicrob Agents Chemother</i>. Published online October 7, 2019. doi:10.1128/AAC.01102-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31591117/pubmed" id="31591117" target="_blank">31591117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet.</i> 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21521866">
<a name="21521866"></a>Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it dose- or duration-related? <i>Ann Pharmacother</i>. 2011;45(5):629‐638. doi:10.1345/aph.1P583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21521866/pubmed" id="21521866" target="_blank">21521866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183‐198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29909695">
<a name="29909695"></a>Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. <i>Expert Rev Anti Infect Ther</i>. 2018;16(7):565-578. doi: 10.1080/14787210.2018.1489722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29909695/pubmed" id="29909695" target="_blank">29909695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26260647">
<a name="26260647"></a>Bose S, Wurm E, Popovich MJ, Silver BJ. Drug-induced immune-mediated thrombocytopenia in the intensive care unit. <i>J Clin Anesth</i>. 2015;27(7):602‐605. doi:10.1016/j.jclinane.2015.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26260647/pubmed" id="26260647" target="_blank">26260647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1923224">
<a name="1923224"></a>Bourget P, Fernandez H, Delouis C, et al, "Transplacental Passage of Vancomycin During the Second Trimester of Pregnancy," <i>Obstet Gynecol</i>, 1991, 78(5 Pt 2):908-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1923224/pubmed" id="1923224" target="_blank">1923224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2021">
<a name="Bradley.2021"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24503131">
<a name="24503131"></a>Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by <i>Clostridium difficile</i>. <i>Gastroenterology</i>. 2014;146(6):1547‐1553. doi:10.1053/j.gastro.2014.01.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24503131/pubmed" id="24503131" target="_blank">24503131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94‐105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326‐2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2669623">
<a name="2669623"></a>Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. <i>Antimicrob Agents Chemother</i>. 1989;33(6):791‐796. doi:10.1128/aac.33.6.791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2669623/pubmed" id="2669623" target="_blank">2669623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2294943">
<a name="2294943"></a>Brummett RE, Fox KE, Jacobs F, Kempton JB, Stokes Z, Richmond AB. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. <i>Arch Otolaryngol Head Neck Surg</i>. 1990;116(1):61‐64. doi:10.1001/archotol.1990.01870010065019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2294943/pubmed" id="2294943" target="_blank">2294943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25753888">
<a name="25753888"></a>Bruniera FR, Ferreira FM, Saviolli LR, et al. The use of vancomycin with its therapeutic and adverse effects: a review. <i>Eur Rev Med Pharmacol Sci</i>. 2015;19(4):694‐700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25753888/pubmed" id="25753888" target="_blank">25753888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12739981">
<a name="12739981"></a>Buck ML, "Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates," <i>Clin Pharmacokinet</i>, 2003, 42(5):403-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12739981/pubmed" id="12739981" target="_blank">12739981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9758319">
<a name="9758319"></a>Buck ML, "Vancomycin Pharmacokinetics in Neonates Receiving Extracorporeal Membrane Oxygenation," <i>Pharmacotherapy</i>, 1998, 18(5):1082-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9758319/pubmed" id="9758319" target="_blank">9758319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6627823">
<a name="6627823"></a>Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. <i>Clin Pharmacol Ther</i>. 1983;34(5):631-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/6627823/pubmed" id="6627823" target="_blank">6627823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27148613">
<a name="27148613"></a>Butler M, Olson A, Drekonja D, et al; Agency for Healthcare Research and Quality (US). Early diagnosis, prevention, and treatment of <i>Clostridium difficile</i>: update. Comparative effectiveness review No. 172. <a href="https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0087162/" target="_blank">https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0087162/</a>. Published March 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27148613/pubmed" id="27148613" target="_blank">27148613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21592453">
<a name="21592453"></a>Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. <i>Am J Med</i>. 2011;124(7):588‐597. doi:10.1016/j.amjmed.2011.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21592453/pubmed" id="21592453" target="_blank">21592453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11549096">
<a name="11549096"></a>Capparelli EV, Lane JR, Romanowski GL, et al, "The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants," <i>J Clin Pharmacol</i>, 2001, 41(9):927-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11549096/pubmed" id="11549096" target="_blank">11549096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carmichael.1986">
<a name="Carmichael.1986"></a>Carmichael AJ, Al-Zahawi MF. Pancytopenia associated with vancomycin. <i>Br Med J</i>. 1986;293:1103.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25220436">
<a name="25220436"></a>Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now?. <i>Pharmacotherapy</i>. 2014;34(12):1259‐1268. doi:10.1002/phar.1488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25220436/pubmed" id="25220436" target="_blank">25220436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21088663">
<a name="21088663"></a>Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease, revised guidelines from CDC, 2010. <i>MMWR Recomm Rep</i>. 2010; 59(RR-10):1-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21088663/pubmed" id="21088663" target="_blank">21088663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff</i>. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. March 27, 2020. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference">
                  Chang D, "Influence of Malignancy on the Pharmacokinetics of Vancomycin in Infants and Children," <i>Pediatr Infect Dis J</i>, 1995, 14(8):667-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/ 8532423 /pubmed" id=" 8532423 " target="_blank"> 8532423 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7845750">
<a name="7845750"></a>Chang D, Liem L, and Malogolowkin M, "A Prospective Study of Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients," <i>Pediatr Infect Dis J</i>, 1994, 13(11):969-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7845750/pubmed" id="7845750" target="_blank">7845750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21273948">
<a name="21273948"></a>Changela A, Javaiya H, Rickenback K, Elnawawi A, Changela K. Toxic epidermal necrolyis after vancomycin use: a case report and discussion of management. <i>Am J Ther</i>. 2013;20(2):223‐225. doi:10.1097/MJT.0b013e3181f94c27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21273948/pubmed" id="21273948" target="_blank">21273948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10875494">
<a name="10875494"></a>Chopra N, Oppenheimer J, Derimanov GS, Fine PL. Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels. <i>Ann Allergy Asthma Immunol</i>. 2000;84(6):633‐635. doi:10.1016/S1081-1206(10)62416-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/10875494/pubmed" id="10875494" target="_blank">10875494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chu.1">
<a name="Chu.1"></a>Chu VH. Staphylococcal toxic shock syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28650363">
<a name="28650363"></a>Cies JJ, Moore WS 2nd, Nichols K, Knoderer CA, Carella DM, Chopra A. Population pharmacokinetics and pharmacodynamic target attainment of vancomycin in neonates on extracorporeal life support. <i>Pediatr Crit Care Med</i>. 2017;18(10):977-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28650363/pubmed" id="28650363" target="_blank">28650363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141‐1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19558257">
<a name="19558257"></a>Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. <i>Pharmacotherapy</i>. 2009;29(7):832-845.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19558257/pubmed" id="19558257" target="_blank">19558257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31888350">
<a name="31888350"></a>Covvey JR, Erickson O, Fiumara D, et al. Comparison of vancomycin area-under-the-curve dosing versus trough target-based dosing in obese and nonobese patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>Ann Pharmacother</i>. 2020;54(7):644-651. doi:10.1177/1060028019897100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31888350/pubmed" id="31888350" target="_blank">31888350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30203073">
<a name="30203073"></a>Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. <i>J Antimicrob Chemother.</i> 2018;73(11):3081-3086. doi:10.1093/jac/dky310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30203073/pubmed" id="30203073" target="_blank">30203073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767246">
<a name="15767246"></a>Craycraft ME, Arunakul VL, Humeniuk JM. Probable vancomycin-associated toxic epidermal necrolysis. <i>Pharmacotherapy</i>. 2005;25(2):308‐312. doi:10.1592/phco.25.2.308.56953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15767246/pubmed" id="15767246" target="_blank">15767246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26490819">
<a name="26490819"></a>Crew P, Heintz SJ, Heintz BH. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis.<i> Am J Health Syst Pharm.</i> 2015;72(21):1856-1864. doi:10.2146/ajhp150051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26490819/pubmed" id="26490819" target="_blank">26490819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216073">
<a name="27216073"></a>Cristallini S, Hites M, Kabtouri H, et al. New regimen for continuous infusion of vancomycin in critically ill patients. <i>Antimicrob Agents Chemother.</i> 2016;60(8):4750-4756. doi:10.1128/AAC.00330-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27216073/pubmed" id="27216073" target="_blank">27216073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31108184">
<a name="31108184"></a>Dao K, Guidi M, André P, et al. Optimisation of vancomycin exposure in neonates based on the best level of evidence. <i>Pharmacol Res</i>. 2020;154:104278. doi:10.1016/j.phrs.2019.104278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31108184/pubmed" id="31108184" target="_blank">31108184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15139793">
<a name="15139793"></a>de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. <i>Clin Pharmacokinet.</i> 2004;43(7):417-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15139793/pubmed" id="15139793" target="_blank">15139793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24118601">
<a name="24118601"></a>Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. <i>Clin Microbiol Infect</i>. 2014;20(suppl 2):1-26. doi: 10.1111/1469-0691.12418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24118601/pubmed" id="24118601" target="_blank">24118601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23880743">
<a name="23880743"></a>Denaburg M, Patel S. Salvage antibiotic-lock therapy in critically ill pediatric patients: a pharmacological review for pediatric intensive care unit nurses. <i>AACN Adv Crit Care</i>. 2013;24(3):233-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23880743/pubmed" id="23880743" target="_blank">23880743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951‐1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30174327">
<a name="30174327"></a>di Fonzo H, Villegas Gutsch M, Castroagudin A, Cabrera MV, Mazzei ME, Rueda D. Agranulocytosis induced by vancomycin. Case report and literature review. <i>Am J Case Rep</i>. 2018;19:1053‐1056. doi:10.12659/AJCR.909956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30174327/pubmed" id="30174327" target="_blank">30174327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24926475">
<a name="24926475"></a>Domis MJ, Moritz ML. Red man syndrome following intraperitoneal vancomycin in a child with peritonitis. <i>Front Pediatr</i>. 2014;2:55. doi:10.3389/fped.2014.00055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24926475/pubmed" id="24926475" target="_blank">24926475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31369087">
<a name="31369087"></a>Downes KJ, Hayes M, Fitzgerald JC, et al. Mechanisms of antimicrobial-induced nephrotoxicity in children. <i>J Antimicrob Chemother</i>. 2020;75(1):1‐13. doi:10.1093/jac/dkz325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31369087/pubmed" id="31369087" target="_blank">31369087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drew.1">
<a name="Drew.1"></a>Drew RH, Sakoulas G. Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22170976">
<a name="22170976"></a>Duff JM, Moreb JS, Muwalla F. Severe neutropenia following a prolonged course of vancomycin that progressed to agranulocytosis with drug reexposure. <i>Ann Pharmacother</i>. 2012;46(1):e1. doi:10.1345/aph.1Q467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22170976/pubmed" id="22170976" target="_blank">22170976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Durand.1">
<a name="Durand.1"></a>Durand M. Bacterial endophthalmitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22411630">
<a name="22411630"></a>Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. <i>Eur J Clin Pharmacol</i>. 2012;68(9):1243‐1255. doi:10.1007/s00228-012-1259-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22411630/pubmed" id="22411630" target="_blank">22411630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7487614">
<a name="7487614"></a>Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. <i>Arch Ophthalmol.</i> 1995;113(12):1479-1496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7487614/pubmed" id="7487614" target="_blank">7487614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM Jr. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28474732">
<a name="28474732"></a>Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. <i>Clin Pharmacol Ther</i>. 2017;102(3):459‐469. doi:10.1002/cpt.726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28474732/pubmed" id="28474732" target="_blank">28474732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29280786">
<a name="29280786"></a>Fiorito TM, Luther MK, Dennehy PH, LaPlante KL, Matson KL. Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis. <i>Pediatr Infect Dis J.</i> 2018;37(7):654-661. doi:10.1097/INF.0000000000001882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29280786/pubmed" id="29280786" target="_blank">29280786</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Firvanq (vancomycin hydrochloride) [prescribing information]. Wilmington, MA: Azurity Pharmaceuticals; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19729669">
<a name="19729669"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med</i>. 2009;180(9):802-808. doi: 10.1164/rccm.200812-1845PP.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19729669/pubmed" id="19729669" target="_blank">19729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19001107">
<a name="19001107"></a>Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. <i>Antimicrob Agents Chemother</i>. 2009;53(2):483‐486. doi:10.1128/AAC.01088-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19001107/pubmed" id="19001107" target="_blank">19001107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2139270">
<a name="2139270"></a>Forrence EA, Goldman MP. Vancomycin-associated exfoliative dermatitis. <i>DICP</i>. 1990;24(4):369‐371. doi:10.1177/106002809002400405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2139270/pubmed" id="2139270" target="_blank">2139270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1543783">
<a name="1543783"></a>Freiman JP, Graham DJ, Reed TG, McGoodwin EB. Chemical peritonitis following the intraperitoneal administration of vancomycin. <i>Perit Dial Int</i>. 1992;12(1):57‐60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1543783/pubmed" id="1543783" target="_blank">1543783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23652479">
<a name="23652479"></a>Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. <i>Pediatr Infect Dis J</i>. 2013;32(10):1077-1079.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23652479/pubmed" id="23652479" target="_blank">23652479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19295465">
<a name="19295465"></a>Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. <i>Pediatr Infect Dis J</i>. 2009;28(5):398-402. doi: 10.1097/INF.0b013e3181906e40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19295465/pubmed" id="19295465" target="_blank">19295465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25136027">
<a name="25136027"></a>Frymoyer A, Hersh AL, El-Komy MH, et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. <i>Antimicrob Agents Chemother</i>. 2014;58(11):6454-6461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25136027/pubmed" id="25136027" target="_blank">25136027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29294072">
<a name="29294072"></a>Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. <i>J Pediatric Infect Dis Soc</i>. 2019;8(2):97-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29294072/pubmed" id="29294072" target="_blank">29294072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11673290">
<a name="11673290"></a>Gan IM, van Dissel JT, Beekhuis H, Swart W, van Meurs JC. Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis. <i>Br J Ophthalmol.</i> 2001;85(11):1289-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11673290/pubmed" id="11673290" target="_blank">11673290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29394210">
<a name="29394210"></a>Genuini M, Oualha M, Bouazza N, et al. Achievement of therapeutic vancomycin exposure with continuous infusion in critically ill children. <i>Pediatr Crit Care Med</i>. 2018;19(6):e263-e269. doi:10.1097/PCC.0000000000001474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29394210/pubmed" id="29394210" target="_blank">29394210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461771">
<a name="15461771"></a>Gilmore ES, Friedman JS, Morrell DS. Extensive fixed drug eruption secondary to vancomycin. <i>Pediatr Dermatol</i>. 2004;21(5):600‐602. doi:10.1111/j.0736-8046.2004.21516.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15461771/pubmed" id="15461771" target="_blank">15461771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Girand.2019">
<a name="Girand.2019"></a>Girand HL. Antibiotic lock therapy for treatment of catheter-related bloodstream infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 9, 2019.</div>
</li>
<li>
<div class="reference">
                  Girand HL. Continuous infusion vancomycin in pediatric patients: a critical review of the evidence. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):198-214. doi:10.5863/1551-6776-25.3.198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32265603/pubmed" id="32265603" target="_blank">32265603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.1">
<a name="Goldenberg.1"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>. Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3712916">
<a name="3712916"></a>Goodpasture HC, Dolan PJ Jr, Jacobs ER, Meredith WT. Pseudomembranous colitis &amp; antibiotics. <i>Kans Med</i>. 1986;87(5):133-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3712916/pubmed" id="3712916" target="_blank">3712916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29366615">
<a name="29366615"></a>Gottlieb M, Long B, Koyfman A. The evaluation and management of toxic shock syndrome in the emergency department: a review of the literature. <i>J Emerg Med.</i> 2018;54(6):807-814. doi: 10.1016/j.jemermed.2017.12.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29366615/pubmed" id="29366615" target="_blank">29366615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al; Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy [published correction appears in <i>J Antimicrob Chemother</i>. 2012;67(5)1304]. <i>J Antimicrob Chemother.</i> 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27631462">
<a name="27631462"></a>Guilhaumou R, Marsot A, Dupouey J, et al. Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization. <i>Ther Drug Monit</i>. 2016;38(5):559-566. doi:10.1097/FTD.0000000000000318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27631462/pubmed" id="27631462" target="_blank">27631462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27192600">
<a name="27192600"></a>Gupta S, Sharma S, Menon N, Ahuja S, Dahdouh M. Case report of vancomycin-induced pancytopenia. <i>Rev Soc Bras Med Trop</i>. 2016;49(2):258‐259. doi:10.1590/0037-8682-0263-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27192600/pubmed" id="27192600" target="_blank">27192600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180478">
<a name="31180478"></a>Gwee A, Cranswick N, McMullan B, et al. Defining target vancomycin trough concentrations for treating Staphylococcus aureus infection in infants aged 0 to 90 days. <i>JAMA Pediatr</i>. 2019;173(8):791-793. doi:10.1001/jamapediatrics.2019.1488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31180478/pubmed" id="31180478" target="_blank">31180478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35037934">
<a name="35037934"></a>Gwee A, Duffull SB, Daley AJ, et al. Identifying a therapeutic target for vancomycin against staphylococci in young infants. <i>J Antimicrob Chemother</i>. 2022;77(3):704-710. doi:10.1093/jac/dkab469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/35037934/pubmed" id="35037934" target="_blank">35037934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320109">
<a name="26320109"></a>Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>Eur Heart J</i>. 2015;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26320109/pubmed" id="26320109" target="_blank">26320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1659305">
<a name="1659305"></a>Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on <i>Enterococcus faecalis</i> and <i>Staphylococcus aureus</i> demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. <i>Antimicrob Agents Chemother.</i> 1991;35(9):1710-1716. doi:10.1128/aac.35.9.1710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1659305/pubmed" id="1659305" target="_blank">1659305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11317179">
<a name="11317179"></a>Hassaballa H, Mallick N, Orlowski J. Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome. <i>Am J Ther</i>. 2000;7(5):319‐320. doi:10.1097/00045391-200007050-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11317179/pubmed" id="11317179" target="_blank">11317179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1693055">
<a name="1693055"></a>Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. <i>Antimicrob Agents Chemother</i>. 1990;34(4):550-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/1693055/pubmed" id="1693055" target="_blank">1693055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31725118">
<a name="31725118"></a>Hecht SM, Ardura MI, Yildiz VO, Ouellette CP. Central venous catheter management in high-risk children with bloodstream infections. <i>Pediatr Infect Dis J</i>. 2020;39(1):17-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31725118/pubmed" id="31725118" target="_blank">31725118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2910675">
<a name="2910675"></a>Hecht JR, Olinger EJ. <i>Clostridium difficile</i> colitis secondary to intravenous vancomycin. <i>Dig Dis Sci</i>. 1989;34(1):148‐149. doi:10.1007/BF01536172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2910675/pubmed" id="2910675" target="_blank">2910675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19209277">
<a name="19209277"></a>Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of <i>Clostridium difficile</i> infection (CDI). <i>Ther Clin Risk Manag</i>. 2008;4(5):949‐964. doi:10.2147/tcrm.s3145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19209277/pubmed" id="19209277" target="_blank">19209277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30333114">
<a name="30333114"></a>Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. <i>Am J Health Syst Pharm</i>. 2018;75(24):1986-1995. doi: 10.2146/ajhp180034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30333114/pubmed" id="30333114" target="_blank">30333114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742‐748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14570656">
<a name="14570656"></a>Hepner DL, Castells MC. Anaphylaxis during the perioperative period. <i>Anesth Analg</i>. 2003;97(5):1381‐1395. doi:10.1213/01.ane.0000082993.84883.7d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/14570656/pubmed" id="14570656" target="_blank">14570656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34843669">
<a name="34843669"></a>Hill LF, Clements MN, Turner MA, et al. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. <i>Lancet Child Adolesc Health</i>. 2022;6(1):49-59. doi:10.1016/S2352-4642(21)00305-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/34843669/pubmed" id="34843669" target="_blank">34843669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2225752">
<a name="2225752"></a>Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. <i>Clin Pharm</i>. 1990;9(9):711-715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2225752/pubmed" id="2225752" target="_blank">2225752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23335735">
<a name="23335735"></a>Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with staphylococcus aureus bacteremia. <i>Antimicrob Agents Chemother.</i> 2013;57(4):1654-1663. doi:10.1128/AAC.01485-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23335735/pubmed" id="23335735" target="_blank">23335735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26011138">
<a name="26011138"></a>Hong J, Krop LC, Johns T, Pai MP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. <i>Pharmacotherapy</i>. 2015;35(5):455-463. doi:10.1002/phar.1588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26011138/pubmed" id="26011138" target="_blank">26011138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22017186">
<a name="22017186"></a>Hsiao SH, Chou CH, Lin WL, et al. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. <i>J Clin Pharm Ther</i>. 2012;37(3):296‐300. doi:10.1111/j.1365-2710.2011.01291.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22017186/pubmed" id="22017186" target="_blank">22017186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19843487">
<a name="19843487"></a>Hung YP, Lee NY, Chang CM, et al. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review. <i>Clin Ther</i>. 2009;31(9):1977‐1986. doi:10.1016/j.clinthera.2009.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19843487/pubmed" id="19843487" target="_blank">19843487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718415">
<a name="29718415"></a>Hurst AL, Baumgartner C, MacBrayne CE, Child J. Experience with continuous infusion vancomycin dosing in a large pediatric hospital. <i>J Pediatric Infect Dis Soc</i>. 2019;8(2):174-179. doi:10.1093/jpids/piy032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29718415/pubmed" id="29718415" target="_blank">29718415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24884581">
<a name="24884581"></a>Iwata K, Doi A, Fukuchi T, et al. A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus. <i>BMC Infect Dis.</i> 2014;14:247-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24884581/pubmed" id="24884581" target="_blank">24884581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31049551">
<a name="31049551"></a>Jacqz-Aigrain E, Leroux S, Thomson AH, et al. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>J Antimicrob Chemother</i>. 2019;74(8):2128-2138. doi:10.1093/jac/dkz158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31049551/pubmed" id="31049551" target="_blank">31049551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28168063">
<a name="28168063"></a>Jha P, Swanson K, Stromich J, Michalski BM, Olasz E. A rare case of vancomycin-induced linear immunoglobulin a bullous dermatosis. <i>Case Rep Dermatol Med</i>. 2017;2017:7318305. doi:10.1155/2017/7318305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28168063/pubmed" id="28168063" target="_blank">28168063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164674">
<a name="34164674"></a>Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. <i>Clin Infect Dis</i>. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/34164674/pubmed" id="34164674" target="_blank">34164674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29263057">
<a name="29263057"></a>Jumah MTB, Vasoo S, Menon SR, De PP, Neely M, Teng CB. Pharmacokinetic/pharmacodynamic determinants of vancomycin efficacy in <i>Enterococcal</i> bacteremia. <i>Antimicrob Agents Chemother.</i> 2018;62(3). doi:10.1128/AAC.01602-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29263057/pubmed" id="29263057" target="_blank">29263057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25548523">
<a name="25548523"></a>Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. <i>Infect Drug Resist</i>. 2014;7:343-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25548523/pubmed" id="25548523" target="_blank">25548523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kelly.1">
<a name="Kelly.1"></a>Kelly CP, Lamont JT, Bakken JS. Clostridioides difficile in adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34003176">
<a name="34003176"></a>Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. <i>Am J Gastroenterol</i>. 2021b;116(6):1124-1147. doi:10.14309/ajg.0000000000001278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/34003176/pubmed" id="34003176" target="_blank">34003176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31356340">
<a name="31356340"></a>Khicher S, Weinberger JJ. Vancomycin-associated erythema multiforme. <i>Am J Ther</i>. 2019. doi:10.1097/MJT.0000000000001038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31356340/pubmed" id="31356340" target="_blank">31356340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27546217">
<a name="27546217"></a>Kim AJ, Lee JY, Choi SA, Shin WG. Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients. <i>Int J Antimicrob Agents.</i> 2016;48(4):381-387. doi:10.1016/j.ijantimicag.2016.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27546217/pubmed" id="27546217" target="_blank">27546217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31722513">
<a name="31722513"></a>Kim BK, Kim JH, Sohn KH, Kim JY, Chang YS, Kim SH. Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors. <i>Korean J Intern Med</i>. 2020;35(3):714‐722. doi:10.3904/kjim.2018.404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31722513/pubmed" id="31722513" target="_blank">31722513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12503934">
<a name="12503934"></a>Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. <i>Ann Pharmacother</i>. 2003;37(1):61‐65. doi:10.1345/aph.1C145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12503934/pubmed" id="12503934" target="_blank">12503934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30776417">
<a name="30776417"></a>Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. <i>J Allergy Clin Immunol</i>. 2019;144(1):183‐192. doi:10.1016/j.jaci.2019.01.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30776417/pubmed" id="30776417" target="_blank">30776417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21460309">
<a name="21460309"></a>Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. <i>Clin Infect Dis.</i> 2011;52(8):975-981. doi:10.1093/cid/cir124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21460309/pubmed" id="21460309" target="_blank">21460309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20234160">
<a name="20234160"></a>Kupstaite R, Baranauskaite A, Pileckyte M, Sveikata A, Kadusevicius E, Muckiene G. Severe vancomycin-induced anaphylactic reaction. <i>Medicina (Kaunas)</i>. 2010;46(1):30‐33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20234160/pubmed" id="20234160" target="_blank">20234160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31709893">
<a name="31709893"></a>Langton MM, Ahern JW, MacDougall J. An AUC target simulation for vancomycin in patients with class III obesity.<i> J Pharm Pract.</i> Published online November 10, 2019. doi:10.1177/0897190019885241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31709893/pubmed" id="31709893" target="_blank">31709893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17403700">
<a name="17403700"></a>LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. <i>Nephrol Dial Transplant</i>. 2007;22(8):2239-2246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/17403700/pubmed" id="17403700" target="_blank">17403700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12225605">
<a name="12225605"></a>Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. <i>Crit Care</i>. 2002;6(4):313-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12225605/pubmed" id="12225605" target="_blank">12225605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23340565">
<a name="23340565"></a>Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure.<i> Pediatr Infect Dis J</i>. 2013;32(4):e155-163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23340565/pubmed" id="23340565" target="_blank">23340565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26582878">
<a name="26582878"></a>Le J, Ny P, Capparelli E, et al. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. <i>J Pediatric Infect Dis Soc</i>. 2015;4(4):e109-e116. doi:10.1093/jpids/piu110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26582878/pubmed" id="26582878" target="_blank">26582878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16556639">
<a name="16556639"></a>Lee JY, Ko KS, Peck KR, Oh WS, Song JH. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. <i>J Antimicrob Chemother</i>. 2006;57(6):1110-1115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/16556639/pubmed" id="16556639" target="_blank">16556639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2657617">
<a name="2657617"></a>Leonard MB, Koren G, Stevenson DK, et al, "Vancomycin Pharmacokinetics in Very Low Birth Weight Neonates," <i>Pediatr Infect Dis J</i>, 1989, 8(5):282-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2657617/pubmed" id="2657617" target="_blank">2657617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7687945">
<a name="7687945"></a>Levy JH, Marty AT. Vancomycin and adverse drug reactions. <i>Crit Care Med</i>. 1993;21(8):1107‐1108. doi:10.1097/00003246-199308000-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7687945/pubmed" id="7687945" target="_blank">7687945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25627406">
<a name="25627406"></a>Lin Wu FL, Liu SS, Yang TY, et al. A larger dose of vancomycin is required in adult neurosurgical intensive care unit patients due to augmented clearance. <i>Ther Drug Monit.</i> 2015;37(5):609-618. doi:10.1097/FTD.0000000000000187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25627406/pubmed" id="25627406" target="_blank">25627406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20628102">
<a name="20628102"></a>Li PK, Szeto CC, Piraino B, et al. International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. <i>Perit Dial Int</i>. 2010;30(4):393-423. doi: 10.3747/pdi.2010.00049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20628102/pubmed" id="20628102" target="_blank">20628102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. <i>Perit Dial Int</i>. 2016;36(5):481-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24599767">
<a name="24599767"></a>Lin YF, Yang CH, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. <i>Clin Infect Dis</i>. 2014;58(10):1377‐1385. doi:10.1093/cid/ciu126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24599767/pubmed" id="24599767" target="_blank">24599767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19609675">
<a name="19609675"></a>Lin Z, Kotler DP, Schlievert PM, Sordillo EM. Staphylococcal enterocolitis: forgotten but not gone? <i>Dig Dis Sci</i>. 2010;55(5):1200-1207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19609675/pubmed" id="19609675" target="_blank">19609675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis</i>. 2012;54(12):e132-73. doi: 10.1093/cid/cis346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis.</i> 2011;52(3):285-292. doi: 10.1093/cid/cir034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24867791">
<a name="24867791"></a>Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections: how much is enough? <i>Clin Infect Dis.</i> 2014;59(5):666-675. doi:10.1093/cid/ciu398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24867791/pubmed" id="24867791" target="_blank">24867791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18227177">
<a name="18227177"></a>Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. <i>Antimicrob Agents Chemother</i>. 2008;52(4):1330-1336. doi: 10.1128/AAC.01602-07.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/18227177/pubmed" id="18227177" target="_blank">18227177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19586413">
<a name="19586413"></a>Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. <i>Clin Infect Dis</i>. 2009;49(4):507‐514. doi:10.1086/600884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19586413/pubmed" id="19586413" target="_blank">19586413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31157370">
<a name="31157370"></a>Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The emperor's new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infections (PROVIDE). <i>Clin Infect Dis</i>. 2020;70(8):1536-1545. doi:10.1093/cid/ciz460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31157370/pubmed" id="31157370" target="_blank">31157370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9756787">
<a name="9756787"></a>Löwdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>. <i>Antimicrob Agents Chemother.</i> 1998;42(10):2739-2744. doi:10.1128/AAC.42.10.2739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9756787/pubmed" id="9756787" target="_blank">9756787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12198218">
<a name="12198218"></a>Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. <i>Nephrol Dial Transplant.</i> 2002;17(9):1649-1654. doi:10.1093/ndt/17.9.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12198218/pubmed" id="12198218" target="_blank">12198218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2018;38(4):309-310. doi: 10.3747/pdi.2018.00026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9391687">
<a name="9391687"></a>Mandl DL, Garrison MW, Palpant SD. Agranulocytosis induced by vancomycin or ticarcillin/clavulanate. <i>Ann Pharmacother</i>. 1997;31(11):1321‐1324. doi:10.1177/106002809703101109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9391687/pubmed" id="9391687" target="_blank">9391687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9399623">
<a name="9399623"></a>Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. <i>Pharmacotherapy</i>. 1997;17(6):1341‐1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9399623/pubmed" id="9399623" target="_blank">9399623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22149255">
<a name="22149255"></a>Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetic analyses. <i>Clin Pharmacokinet.</i> 2012;51(1):1-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22149255/pubmed" id="22149255" target="_blank">22149255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8878246">
<a name="8878246"></a>Martí R, Rosell M, Pou L, Garcia L, Pascual C. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. <i>Pharmacol Toxicol.</i> 1996;79(2):55-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8878246/pubmed" id="8878246" target="_blank">8878246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26039127">
<a name="26039127"></a>Matsunaga N, Hisata K, Shimizu T. An investigation into the vancomycin concentration in the cerebrospinal fluid due to vancomycin intraventricular administration in newborns: a study of 13 cases. <i>Medicine (Baltimore)</i>. 2015;94(22):e922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26039127/pubmed" id="26039127" target="_blank">26039127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6732213">
<a name="6732213"></a>Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. <i>Antimicrob Agents Chemother.</i> 1984;25(4):433-437. doi:10.1128/aac.25.4.433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/6732213/pubmed" id="6732213" target="_blank">6732213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3530582">
<a name="3530582"></a>Matzke GR, Zhanel GG, and Guay DRP, "Clinical Pharmacokinetics of Vancomycin," <i>Clin Pharmacokinet</i>, 1986, 11(4):257-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3530582/pubmed" id="3530582" target="_blank">3530582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26561525">
<a name="26561525"></a>Mawri S, Jain T, Shah J, Hurst G, Swiderek J. Vancomycin-induced acute generalized exanthematous pustulosis (AGEP) masquerading septic shock-an unusual presentation of a rare disease. <i>J Intensive Care</i>. 2015;3:47. doi:10.1186/s40560-015-0114-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26561525/pubmed" id="26561525" target="_blank">26561525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3971208">
<a name="3971208"></a>Mayhew JF, Deutsch S. Cardiac arrest following administration of vancomycin. <i>Can Anaesth Soc J</i>. 1985;32(1):65‐66. doi:10.1007/BF03008541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3971208/pubmed" id="3971208" target="_blank">3971208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562266">
<a name="29562266"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):987‐994. doi:10.1093/cid/ciy149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29562266/pubmed" id="29562266" target="_blank">29562266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23172265">
<a name="23172265"></a>McKamy S, Chen T, Lee M, Ambrose PJ. Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. <i>Am J Health Syst Pharm</i>. 2012;69(23):2066-2071. doi:10.2146/ajhp120072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23172265/pubmed" id="23172265" target="_blank">23172265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26731739">
<a name="26731739"></a>Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. <i>PLoS One</i>. 2016;11(1):e0146224. doi: 10.1371/journal.pone.0146224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26731739/pubmed" id="26731739" target="_blank">26731739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27681233">
<a name="27681233"></a>Min Z, Garcia RR, Murillo M, Uchin JM, Bhanot N. Vancomycin-associated Henoch-Schönlein purpura. <i>J Infect Chemother</i>. 2017;23(3):180‐184. doi:10.1016/j.jiac.2016.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27681233/pubmed" id="27681233" target="_blank">27681233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27156746">
<a name="27156746"></a>Minhas JS, Wickner PG, Long AA, Banerji A, Blumenthal KG. Immune-mediated reactions to vancomycin: A systematic case review and analysis. <i>Ann Allergy Asthma Immunol</i>. 2016;116(6):544‐553. doi:10.1016/j.anai.2016.03.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27156746/pubmed" id="27156746" target="_blank">27156746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27572807">
<a name="27572807"></a>Miyazu D, Kodama N, Yamashita D, et al. DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration: a case report. <i>Am J Case Rep</i>. 2016;17:625‐631. doi:10.12659/ajcr.899149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27572807/pubmed" id="27572807" target="_blank">27572807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30063652">
<a name="30063652"></a>Moffett BS, Morris J, Galati M, Munoz F, Arikan AA. Population pharmacokinetics of vancomycin in pediatric extracorporeal membrane oxygenation. <i>Pediatr Crit Care Med</i>. 2018;19(10):973-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30063652/pubmed" id="30063652" target="_blank">30063652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27848200">
<a name="27848200"></a>Mohammadi M, Jahangard-Rafsanjani Z, Sarayani A, Hadjibabaei M, Taghizadeh-Ghehi M. Vancomycin-induced thrombocytopenia: a narrative review. <i>Drug Saf</i>. 2017;40(1):49‐59. doi:10.1007/s40264-016-0469-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27848200/pubmed" id="27848200" target="_blank">27848200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509186">
<a name="15509186"></a>Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. <i>Clin Pharmacokinet.</i> 2004;43(13):925-942. doi:10.2165/00003088-200443130-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15509186/pubmed" id="15509186" target="_blank">15509186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16120065">
<a name="16120065"></a>Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. <i>Br J Clin Pharmacol</i>. 2005;60(3):265-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/16120065/pubmed" id="16120065" target="_blank">16120065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32266599">
<a name="32266599"></a>Mulubwa M, Griesel HA, Mugabo P, Dippenaar R, van Wyk L. Assessment of vancomycin pharmacokinetics and dose regimen optimisation in preterm neonates. <i>Drugs R D</i>. 2020;20(2):105-113. doi:10.1007/s40268-020-00302-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32266599/pubmed" id="32266599" target="_blank">32266599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murray.1">
<a name="Murray.1"></a>Murray BE, Arias CA, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinupristin-dalfopristin), lipopeptides (daptomycin), and lipoglycopeptides (telavancin). In: Bennett JE, Dolin R, Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.</i> 8th ed. Philadelphia, PA: Elsevier Saunders;2015:377.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29398192">
<a name="29398192"></a>Nagahama Y, VanBeek MJ, Greenlee JDW. Red man syndrome caused by vancomycin powder. <i>J Clin Neurosci</i>. 2018;50:149‐150. doi:10.1016/j.jocn.2018.01.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29398192/pubmed" id="29398192" target="_blank">29398192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11742178">
<a name="11742178"></a>Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of <i>Clostridium difficile</i> colitis in a patient with a diverted colon: report of a case. <i>Dis Colon Rectum</i>. 2001;44(12):1871-1872. doi:10.1007/BF02234471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11742178/pubmed" id="11742178" target="_blank">11742178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2020">
<a name="NICE.2020"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. September 3, 2014. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30072729">
<a name="30072729"></a>Navinés-Ferrer A, Serrano-Candelas E, Lafuente A, Muñoz-Cano R, Martín M, Gastaminza G. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. <i>Sci Rep</i>. 2018;8(1):11628. doi:10.1038/s41598-018-29965-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30072729/pubmed" id="30072729" target="_blank">30072729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29203493">
<a name="29203493"></a>Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. <i>Antimicrob Agents Chemother</i>. 2018;62(2):e02042-17. doi: 10.1128/AAC.02042-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29203493/pubmed" id="29203493" target="_blank">29203493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090839">
<a name="23090839"></a>Ng K, Mabasa VH, Chow I, Ensom MH. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults. <i>Neurocrit Care</i>. 2014;20(1):158-171. doi: 10.1007/s12028-012-9784-z.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23090839/pubmed" id="23090839" target="_blank">23090839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-514426">
<a name="514426"></a>Nielsen HE, Sorensen I, and Hansen HE, “Peritoneal Transport of Vancomycin During Peritoneal Dialysis,” <i>Nephron</i>, 1979, 24(6):274-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/514426/pubmed" id="514426" target="_blank">514426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735094">
<a name="9735094"></a>Nousari HC, Costarangos C, Anhalt GJ. Vancomycin-associated linear IgA bullous dermatosis. <i>Ann Intern Med</i>. 1998;129(6):507‐508. doi:10.7326/0003-4819-129-6-199809150-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9735094/pubmed" id="9735094" target="_blank">9735094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29380499">
<a name="29380499"></a>Nyman HA, Agarwal A, Senekjian HO, Leypoldt JK, Cheung AK. Removal of vancomycin administered during dialysis by a high-flux dialyzer. <i>Hemodial Int.</i> 2018;22(3):383-387. doi:10.1111/hdi.12637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29380499/pubmed" id="29380499" target="_blank">29380499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22333933">
<a name="22333933"></a>Ocampos-Martinez E, Penaccini L, Scolletta S, et al. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients.<i> Int J Antimicrob Agents</i>. 2012;39(4):332-337. doi:10.1016/j.ijantimicag.2011.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22333933/pubmed" id="22333933" target="_blank">22333933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17665503">
<a name="17665503"></a>O'Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. <i>Am J Hematol</i>. 2007;82(12):1122. doi:10.1002/ajh.20916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/17665503/pubmed" id="17665503" target="_blank">17665503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24679944">
<a name="24679944"></a>Onwuchuruba CN, Towers CV, Howard BC, Hennessy MD, Wolfe L, Brown MS. Transplacental passage of vancomycin from mother to neonate. <i>Am J Obstet Gynecol</i>. 2014;210(4):352.e1-352.e4. doi: 10.1016/j.ajog.2014.01.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24679944/pubmed" id="24679944" target="_blank">24679944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3510836">
<a name="3510836"></a>Osler T, Lott D, Bordley J 4th, Lynch F, Ellsworth C, Kozak A. Cefazolin-induced pseudomembranous colitis resulting in perforation of the sigmoid colon. <i>Dis Colon Rectum</i>. 1986;29(2):140-143. doi:10.1007/BF02555402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3510836/pubmed" id="3510836" target="_blank">3510836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26246124">
<a name="26246124"></a>Otani IM, Kuhlen JL Jr, Blumenthal KG, Guyer A, Banerji A. A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis. <i>J Allergy Clin Immunol Pract</i>. 2015;3(6):984‐985. doi:10.1016/j.jaip.2015.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26246124/pubmed" id="26246124" target="_blank">26246124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21782382">
<a name="21782382"></a>Packer M, Chang DF, Dewey SH, et al; ASCRS Cataract Clinical Committee. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. <i>J Cataract Refract Surg.</i> 2011;37(9):1699-1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21782382/pubmed" id="21782382" target="_blank">21782382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29067501">
<a name="29067501"></a>Parasuraman JM, Albur M, Fellows G, Heep A. Monitoring intraventricular vancomycin for ventriculostomy access device infection in preterm infants. <i>Childs Nerv Syst</i>. 2018;34(3):473-479.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29067501/pubmed" id="29067501" target="_blank">29067501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8336766">
<a name="8336766"></a>Pasic M, Jost R, Carrel T, Von Segesser L, Turina M. Intracolonic vancomycin for pseudomembranous colitis. <i>N Engl J Med</i>. 1993;329(8):583. doi:10.1056/NEJM199308193290819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8336766/pubmed" id="8336766" target="_blank">8336766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19223642">
<a name="19223642"></a>Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. <i>Antimicrob Agents Chemother.</i> 2009;53(5):1863-1867. doi:10.1128/AAC.01149-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19223642/pubmed" id="19223642" target="_blank">19223642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PIDS.1">
<a name="PIDS.1"></a>Pediatric Infectious Diseases Society (PIDS). Pediatric Infectious Diseases Society endorses new terminology: vancomycin flushing syndrome. https://pids.org/wp-content/uploads/2021/04/PIDS-Endorses-New-Terminology_Vanc-Flushing-Syn_Final_4.27.21-1.pdf. April 27, 2021. Accessed May 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25689243">
<a name="25689243"></a>Pettit NN, DePestel DD, Fohl AL, et al. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of <i>Clostridium difficile</i> infection. <i>Pharmacotherapy</i>. 2015;35(2):119-126. doi: 10.1002/phar.1538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25689243/pubmed" id="25689243" target="_blank">25689243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29290740">
<a name="29290740"></a>Pettit RS, Peters SJ, McDade EJ, et al. Vancomycin dosing and monitoring in the treatment of cystic fibrosis: results of a National Practice Survey.<i> J Pediatr Pharmacol Ther</i>. 2017;22(6):406-411. doi: 10.5863/1551-6776-22.6.406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29290740/pubmed" id="29290740" target="_blank">29290740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9314470">
<a name="9314470"></a>Pfausler B, Haring HP, Kampfl A, Wissel J, Schober M, Schmutzhard E. Cerebrospinal fluid (CSF) pharmacokinetics of intraventricular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. <i>Clin Infect Dis</i>. 1997;25(3):733-735.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9314470/pubmed" id="9314470" target="_blank">9314470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943633">
<a name="28943633"></a>Pingili CS, Okon EE. Vancomycin-induced leukocytoclastic vasculitis and acute renal failure due to tubulointerstitial nephritis. <i>Am J Case Rep</i>. 2017;18:1024‐1027. doi:10.12659/ajcr.905214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28943633/pubmed" id="28943633" target="_blank">28943633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19638004">
<a name="19638004"></a>Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. <i>Transpl Infect Dis</i>. 2009;11(5):467-470. doi:10.1111/j.1399-3062.2009.00426.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19638004/pubmed" id="19638004" target="_blank">19638004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30341404">
<a name="30341404"></a>Radu L, Bengry T, Akierman A, Alshaikh B, Yusuf K, Dersch-Mills D. Evolution of empiric vancomycin dosing in a neonatal population. <i>J Perinatol</i>. 2018;38(12):1702-1707.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30341404/pubmed" id="30341404" target="_blank">30341404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25813682">
<a name="25813682"></a>Rainkie D, Ensom MH, Carr R. Pediatric assessment of vancomycin empiric dosing (PAVED): a retrospective review. <i>Paediatr Drugs</i>. 2015;17(3):245-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25813682/pubmed" id="25813682" target="_blank">25813682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25712445">
<a name="25712445"></a>Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. <i>Ann Pharmacother</i>. 2015;49(5):557-565. doi: 10.1177/1060028015571163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25712445/pubmed" id="25712445" target="_blank">25712445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reyes.1">
<a name="Reyes.1"></a>Reyes MP and Ostrea EM Jr, "Toxicity of Vancomycin Given During Pregnancy (Reply)," <i>Am J Obstet Gynecol</i>, 1990, 163(4 Pt 1):1376.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2801848">
<a name="2801848"></a>Reyes MP, Ostrea EM Jr, Cabinian AE, et al. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? <i>Am J Obstet Gynecol</i>. 1989;161(4):977-981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2801848/pubmed" id="2801848" target="_blank">2801848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12204187">
<a name="12204187"></a>Rocha JL, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. <i>Braz J Infect Dis</i>. 2002;6(4):196‐200. doi:10.1590/s1413-86702002000400007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12204187/pubmed" id="12204187" target="_blank">12204187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9250422">
<a name="9250422"></a>Rodvold KA, Everett JA, Pryka RD, and Kraus DM, "Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children," <i>Clin Pharmacokinet</i>, 1997, 33(1):32-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9250422/pubmed" id="9250422" target="_blank">9250422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26024909">
<a name="26024909"></a>Rokas KE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. <i>Clin Infect Dis</i>. 2015;61(6):934-941. doi: 10.1093/cid/civ409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26024909/pubmed" id="26024909" target="_blank">26024909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2351627">
<a name="2351627"></a>Rybak MJ, Albrecht LM, Boike SC, et al, "Nephrotoxicity of Vancomycin, Alone and With an Aminoglycoside," <i>J Antimicrob Chemother</i>, 1990, 25(4):679-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/2351627/pubmed" id="2351627" target="_blank">2351627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3769763">
<a name="3769763"></a>Rybak MJ, Boike SC. Monitoring vancomycin therapy. <i>Drug Intell Clin Pharm</i>. 1986;20(10):757-761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3769763/pubmed" id="3769763" target="_blank">3769763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32191793">
<a name="32191793"></a>Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists (ASHP/IDSA/SIDP). <i>Am J Health Syst Pharm</i>. 2020;77(11):835‐864. doi:10.1093/ajhp/zxaa036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32191793/pubmed" id="32191793" target="_blank">32191793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19106348">
<a name="19106348"></a>Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists (ASHP/IDSA/SIDP). <i>Am J Health Syst Pharm</i>. 2009;66(1):82‐98. doi:10.2146/ajhp080434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/19106348/pubmed" id="19106348" target="_blank">19106348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24896763">
<a name="24896763"></a>Saffouri G, Khanna S, Estes L, Pardi D. Outcomes from rectal vancomycin therapy in patients with <i>Clostridium difficile</i> infection. <i>Am J Gastroenterol</i>. 2014;109(6):924-925. doi:10.1038/ajg.2014.80<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24896763/pubmed" id="24896763" target="_blank">24896763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29587650">
<a name="29587650"></a>Sawada A, Kawanishi K, Morikawa S, et al. Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review. <i>BMC Nephrol</i>. 2018;19(1):72. doi:10.1186/s12882-018-0845-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29587650/pubmed" id="29587650" target="_blank">29587650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7350291">
<a name="7350291"></a>Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. <i>J Pediatr</i>. 1980;96(1):119-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7350291/pubmed" id="7350291" target="_blank">7350291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24165255">
<a name="24165255"></a>Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. <i>Am Surg.</i> 2013;79(11):1185-1190. doi:10.1177/000313481307901123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24165255/pubmed" id="24165255" target="_blank">24165255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23277317">
<a name="23277317"></a>Schutze GE, Willoughby RE, Committee on Infectious Diseases, American Academy of Pediatrics. <i>Clostridium difficile</i> infection in infants and children. <i>Pediatrics</i>. 2013;131(1):196-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23277317/pubmed" id="23277317" target="_blank">23277317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9085316">
<a name="9085316"></a>Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA. Effects of dialysis membrane on intradialytic vancomycin administration. <i>Pharmacotherapy</i>. 1997;17(2):256-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/9085316/pubmed" id="9085316" target="_blank">9085316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019a">
<a name="Sexton.2019a"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019b">
<a name="Sexton.2019b"></a>Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 30, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21716699">
<a name="21716699"></a>Shah-Khan F, Scheetz MH, Ghossein C. Biopsy-proven acute tubular necrosis due to vancomycin toxicity. <i>Int J Nephrol</i>. 2011;2011:436856. doi:10.4061/2011/436856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/21716699/pubmed" id="21716699" target="_blank">21716699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082‐1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45‐e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973553">
<a name="24973553"></a>Shokouhi S, Alavi Darazam I. Determination of vancomycin trough level in serum and cerebrospinal fluid of patients with acute community-acquired meningitis: a prospective study. <i>J Infect</i>. 2014;69(5):424-429. doi: 10.1016/j.jinf.2014.06.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24973553/pubmed" id="24973553" target="_blank">24973553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.2019">
<a name="Simon.2019"></a>Simon RH. Cystic fibrosis: Management of pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12720556">
<a name="12720556"></a>Sivagnanam S, Deleu D. Red man syndrome. <i>Crit Care</i>. 2003;7(2):119‐120. doi:10.1186/cc1871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/12720556/pubmed" id="12720556" target="_blank">12720556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29518176">
<a name="29518176"></a>Smetana KS, Cook AM. Cerebrospinal fluid vancomycin dosing and monitoring: the quandary posed by guideline recommendations. <i>Clin Infect Dis</i>. 2018;67(6):980-981. doi: 10.1093/cid/ciy189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29518176/pubmed" id="29518176" target="_blank">29518176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10030777">
<a name="10030777"></a>Smith PF, Taylor CT. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. <i>Pharmacotherapy</i>. 1999;19(2):240‐244. doi:10.1592/phco.19.3.240.30912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/10030777/pubmed" id="10030777" target="_blank">10030777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010;50(12):1695]. <i>Clin Infect Dis. </i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.1">
<a name="Southwick.1"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26116239">
<a name="26116239"></a>Spadaro S, Berselli A, Fogagnolo A, et al. Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction. <i>BMC Anesthesiol.</i> 2015;15:95. doi:10.1186/s12871-015-0065-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/26116239/pubmed" id="26116239" target="_blank">26116239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6703548">
<a name="6703548"></a>Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. <i>Ann Intern Med</i>. 1984;100(4):533-534. doi:10.7326/0003-4819-100-4-533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/6703548/pubmed" id="6703548" target="_blank">6703548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online ahead of print June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25998107">
<a name="25998107"></a>Stockmann C, Hersh AL, Roberts JK, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. <i>Infect Dis Ther</i>. 2015;4(2):187-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25998107/pubmed" id="25998107" target="_blank">25998107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439232">
<a name="23439232"></a>Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. <i>Am J Gastroenterol</i>. 2013;108(4):478-498. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23439232/pubmed" id="23439232" target="_blank">23439232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147106">
<a name="23147106"></a>Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. <i>Chemotherapy</i>. 2012;58(4):308-312. doi:10.1159/000343162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23147106/pubmed" id="23147106" target="_blank">23147106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3986655">
<a name="3986655"></a>Symons NL, Hobbes AF, Leaver HK. Anaphylactoid reactions to vancomycin during anaesthesia: two clinical reports. <i>Can Anaesth Soc J</i>. 1985;32(2):178‐181. doi:10.1007/BF03010047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/3986655/pubmed" id="3986655" target="_blank">3986655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter-related infections-in reply. <i>Perit Dial Int</i>. 2018;38(4):311-312. doi: 10.3747/pdi.2018.00046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8870903">
<a name="8870903"></a>Szymusiak-Mutnick BA, Ross MB. Minimizing the occurrence of red-man syndrome. <i>Am J Health Syst Pharm</i>. 1996;53(17):2098.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/8870903/pubmed" id="8870903" target="_blank">8870903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23829415">
<a name="23829415"></a>Tashima S, Konishi K, Koga H, Hashimoto T. A case of vancomycin-induced linear IgA bullous dermatosis with circulating IgA antibodies to the NC16a domain of BP180. <i>Int J Dermatol</i>. 2014;53(3):e207‐e209. doi:10.1111/ijd.12047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23829415/pubmed" id="23829415" target="_blank">23829415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7283300">
<a name="7283300"></a>Traber PG, Levine DP. Vancomycin Ototoxicity in patient with normal renal function. <i>Ann Intern Med</i>. 1981;95(4):458‐460. doi:10.7326/0003-4819-95-4-458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/7283300/pubmed" id="7283300" target="_blank">7283300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27062204">
<a name="27062204"></a>Trubiano JA, Cheng AC, Korman TM, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. <i>Intern Med J</i>. 2016;46(4):479-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27062204/pubmed" id="27062204" target="_blank">27062204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25311403">
<a name="25311403"></a>Tsai HC, Huang LM, Chang LY, et al. Central venous catheter-associated bloodstream infections in pediatric hematology-oncology patients and effectiveness of antimicrobial lock therapy. <i>J Microbiol Immunol Infect</i>. 2015;48(6):639-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25311403/pubmed" id="25311403" target="_blank">25311403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29358290">
<a name="29358290"></a>Tseng SH, Lim CP, Chen Q, Tang CC, Kong ST, Ho PC. Evaluating the relationship between vancomycin trough concentration and 24-hour area under the concentration-time curve in neonates. <i>Antimicrob Agents Chemother</i>. 2018;62(4):e01647-17. doi:10.1128/AAC.01647-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29358290/pubmed" id="29358290" target="_blank">29358290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tufariello.1">
<a name="Tufariello.1"></a>Tufariello JM, Lowy FD. Infection due to coagulase-negative staphylococci: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online ahead of print February 14, 2017]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill.<i> Clin Pharmacokinet.</i> 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OUHSC.2015">
<a name="OUHSC.2015"></a>University of Oklahoma Health Science Center (OUHSC). Thrombotic thrombocytopenic purpura hemolytic uremic syndrome (TTP-HUS). <a href="https://www.ouhsc.edu/platelets/ditp.html" target="_blank">https://www.ouhsc.edu/platelets/ditp.html.</a> May 4, 2015. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23165462">
<a name="23165462"></a>van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. <i>Antimicrob Agents Chemother</i>. 2013;57(2):734-744. doi:10.1128/AAC.01568-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23165462/pubmed" id="23165462" target="_blank">23165462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vancocin.1">
<a name="Vancocin.1"></a>Vancocin (vancomycin hydrochloride) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vancocin.2">
<a name="Vancocin.2"></a>Vancocin (vancomycin hydrochloride) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vancocin.3">
<a name="Vancocin.3"></a>Vancocin (vancomycin hydrochloride) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; January 2021.</div>
</li>
<li>
<div class="reference">
                  Vancomycin hydrochloride 1.25 g and 1.5 g lyophilized vial [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; February 2023.</div>
</li>
<li>
<div class="reference">
                  Vancomycin hydrochloride fliptop vial 5 g and 10 g pharmacy bulk package [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.1">
<a name="Generic.1"></a>Vancomycin hydrochloride fliptop vial 5 g and 10 g pharmacy bulk package [prescribing information]. Lake Forest, IL: Hospira; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.2">
<a name="Generic.2"></a>Vancomycin hydrochloride injection [prescribing information]. Morgantown, WV: Mylan Institutional LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.3">
<a name="Generic.3"></a>Vancomycin hydrochloride injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.4">
<a name="Generic.4"></a>Vancomycin hydrochloride injection [prescribing information]. Buffalo Grove, IL: Xellia Pharmaceuticals USA, LLC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.5">
<a name="Generic.5"></a>Vancomycin hydrochloride injection [prescribing information]. Buffalo Grove, IL: Xellia Pharmaceuticals USA, LLC; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.6">
<a name="Generic.6"></a>Vancomycin hydrochloride injection [prescribing information]. Columbus, OH: Slate Run Pharmaceuticals; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.7">
<a name="Generic.7"></a>Vancomycin hydrochloride injection [prescribing information]. Rockford, IL: Myland Institutional LLC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.8">
<a name="Generic.8"></a>Vancomycin hydrochloride injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Generic.9">
<a name="Generic.9"></a>Vancomycin hydrochloride lyophilized vial [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1‐10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22915464">
<a name="22915464"></a>Verrall AJ, Llorin R, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. <i>J Antimicrob Chemother</i>. 2012;67(12):2970-2973. doi: 10.1093/jac/dks328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22915464/pubmed" id="22915464" target="_blank">22915464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31110752">
<a name="31110752"></a>Visentainer L, Massuda JY, Cintra ML, Magalhães RF. Vancomycin-induced linear IgA bullous dermatosis (LABD)-an atypical presentation. <i>Clin Case Rep</i>. 2019;7(5):1091‐1093. doi:10.1002/ccr3.2039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31110752/pubmed" id="31110752" target="_blank">31110752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17329697">
<a name="17329697"></a>Von Drygalski A, Curtis BR, Bougie DW, et al. Vancomycin-induced immune thrombocytopenia. <i>N Engl J Med</i>. 2007;356(9):904‐910. doi:10.1056/NEJMoa065066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/17329697/pubmed" id="17329697" target="_blank">17329697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31600554">
<a name="31600554"></a>Vu DH, Nguyen DA, Delattre IK, et al. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: population pharmacokinetic modelling and simulations for improved dosing schemes. <i>Int J Antimicrob Agents.</i> 2019;54(6):702-708. doi:10.1016/j.ijantimicag.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/31600554/pubmed" id="31600554" target="_blank">31600554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25865426">
<a name="25865426"></a>Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. <i>J Clin Pharm Ther</i>. 2015;40(3):259-265. doi: 10.1111/jcpt.12270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/25865426/pubmed" id="25865426" target="_blank">25865426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15550142">
<a name="15550142"></a>Waldman MA, Black DR, Callen JP. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. <i>Clin Exp Dermatol</i>. 2004;29(6):633‐636. doi:10.1111/j.1365-2230.2004.01649.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/15550142/pubmed" id="15550142" target="_blank">15550142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157921">
<a name="11157921"></a>Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. <i>J Antimicrob Chemother</i>. 2001;47(2):246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11157921/pubmed" id="11157921" target="_blank">11157921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int.</i> 2012;(32)(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957‐1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11724099">
<a name="11724099"></a>Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. <i>Ann Pharmacother</i>. 2001;35(11):1458‐1464. doi:10.1345/aph.1A002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/11724099/pubmed" id="11724099" target="_blank">11724099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10488798">
<a name="10488798"></a>Wilhem MP, Estes L. Symposium on antimicrobial agents--Part XII. Vancomycin. <i>Mayo Clin Proc</i>. 1999;74(9):928-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/10488798/pubmed" id="10488798" target="_blank">10488798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24923808">
<a name="24923808"></a>Wolf J, Allison KJ, Tang L, Sun Y, Hayden RT, Flynn PM. No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature. <i>Pediatr Blood Cancer</i>. 2014;61(10):1811-1815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/24923808/pubmed" id="24923808" target="_blank">24923808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30176295">
<a name="30176295"></a>Wolfson AR, Zhou L, Li Y, Phadke NA, Chow OA, Blumenthal KG. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. <i>J Allergy Clin Immunol Pract</i>. 2019;7(2):633‐640. doi:10.1016/j.jaip.2018.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30176295/pubmed" id="30176295" target="_blank">30176295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23215911">
<a name="23215911"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/23215911/pubmed" id="23215911" target="_blank">23215911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084753">
<a name="29084753"></a>Zasowski EJ, Murray KP, Trinh TD, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin.<i> Antimicrob Agents Chemother.</i> 2017;62(1):e01684-17. doi:10.1128/AAC.01684-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/29084753/pubmed" id="29084753" target="_blank">29084753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30181721">
<a name="30181721"></a>Zylbersztajn BL, Izquierdo G, Santana RC, et al. Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support. <i>J Pediatr Pharmacol Ther</i>. 2018;23(4):305-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vancomycin-pediatric-drug-information/abstract-text/30181721/pubmed" id="30181721" target="_blank">30181721</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12874 Version 684.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
